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Apoptosis in Homeostasis & Development 
 
Homeostasis is a critical process for the normal development and survival of 
multicellular eukaryotic organisms.  Regulation of cell growth and cell death is achieved 
by numerous complex cellular signaling pathways, which provide an equilibrium for the 
cell number by affecting the rate of growth and the rate of death in the complex organism 
(Jacobson et al., 1997; Kerr et al., 1972; Meier et al., 2000).  Without a homeostatic 
balance, multicellular organisms can display severe pathological conditions such as 
cancer (Lowe and Lin, 2000; Thompson, 1995). 
In 1972, the description by Kerr, Wyllie and Currie that cells can undergo an 
organized suicide program to achieve cell death was a major breakthrough in our 
understanding of how multicellular organisms develop and achieve homeostasis.  Using 
electron micrographs, the process of cellular death termed apoptosis (Greek origin: apo = 
from, ptosis = falling) was shown to occur in a defined manner, where a cell dying 
through programmed cellular suicide displayed several hallmark features in contrast to a 
cell undergoing unorganized necrotic death.  Kerr and colleagues described apoptosis as a 
non-inflammatory process with characteristic morphological changes including
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chromatin condensation, nuclear and DNA fragmentation, and cellular breakdown into 
defined vesicular bodies that can bleb off and be engulfed by neighboring cells, thus 
minimizing the inflammatory response (Kerr et al., 1972).  
Although the defining morphological events associated with apoptosis were 
described by Kerr and colleagues, Ellis and Horvitz later revealed that apoptosis was a 
genetically regulated process using the classical genetic model organism, the nematode 
worm, Caenorhabditis elegans.  Using mutants of C. elegans, Ellis and Horvitz identified 
two genes, ced-3 and ced-4, necessary for cell death.  Loss of function mutation of ced-3 
or ced-4 inhibited initiation of cell death, and cells harboring these mutations that 
normally underwent programmed cell death during development instead remained alive 
(Ellis and Horvitz, 1986). Subsequent to this finding, Horvitz and colleagues identified an 
additional C. elegans gene, ced-9, that functioned to protect cells from undergoing 
programmed cell death.  C. elegans mutants deficient in ced-9 were embryonic lethal, and 
an activating mutation of ced-9 promoted survival of cells that normally underwent cell 
death during nematode development (Hengartner et al., 1992).  The discovery that these 
genetic mutations impacted the development in C. elegans strengthened the hypothesis 
that cell death was critical for normal development in multicellular organisms.   
Following the detailed characterization of the genetic regulation of programmed 
cell death in C. elegans by Horvitz and colleagues in the late 1980s, and the identification 
of the profound homeostatic and developmental implications associated with activation 
and regulation of cell death, research efforts to understand the genetic and molecular 
components of apoptosis in higher order species increased substantially.  The critical 
effectors and regulators of cell death were subsequently identified in several organisms 
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during the 1990s, including the human and mouse orthologs of ced-3, ced-4 and ced-9, 
and our understanding of the intricate intracellular mechanisms to initiate and regulate 
apoptosis has advanced considerably (Yuan et al., 1993; Tsujimoto et al., 1985; Liu et al., 
1996; Zou et al., 1997).  
 
The Apoptotic Pathways 
 
In the current model of apoptosis, there are a variety of stimuli and cellular insults 
that can induce cell death, including death receptor signaling, ultraviolet light, DNA 
damage, cellular stress, and chemotherapy (Salvesen and Duckett, 2002).  Two major 
cellular pathways that lead to apoptosis have been described, the extrinsic and the 
intrinsic pathway (Figure 1.1).  Although two pathways exist which can lead to apoptosis, 
there is substantial overlap of the molecular components utilized in the extrinsic and 
intrinsic pathways, and these pathways eventually converge at caspase activation (Igney 
and Krammer, 2002).  Furthermore, it has been proposed that the intrinsic or 
mitochondrial pathway can serve as an amplification loop when initiated following 
activation of the extrinsic pathway (Kuwana et al., 1998; Yin et al., 1999).  However, for 
the purpose of demonstrating the mechanisms by which apoptosis can be induced, these 
pathways will be addressed separately, while noting overlapping components and 
converging points between the two pathways. 
The extrinsic pathway involves responses to an intercellular signal or receptor 
ligand.  The primary receptors that respond to intercellular signals to induce cell death are 
members of the tumor necrosis factor (TNF) receptor superfamily, including TNF 
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receptor-1 (TNFR-1) and the Fas receptor (also known as Apo-1 or CD95) (Beutler, 
1999).  Using biochemical analysis, it was determined that both of these TNF receptors 
contain a signature domain within their cytoplasmic tail.  Termed the death domain (DD), 
and now used to define the apoptotic inducing subset of TNF receptors, this domain 
functions to provide a docking site for adaptor molecules, including Fas-associated death 
domain protein (FADD) and TNFR-1-associated death domain protein (TRADD) 
(Chinnaiyan et al., 1995; Boldin et al., 1995a; Boldin et al., 1995b; Hsu et al., 1996).  
FADD and TRADD facilitate the induction of receptor-mediated apoptosis by serving as 
bridges between TNF receptors and cysteine-aspartic acid proteases (caspases), key 
apoptotic machinery molecules that will be discussed more thoroughly below.  The 
associations of Fas, FADD, and caspase-8 are collectively referred to as the death-
inducing signaling complex (DISC), which is a central component of the Fas receptor-
mediated cell death-signaling pathway, since association of the DISC complex promotes 
activation of caspases which leads to execution of cell death (Kischkel et al., 1995).  
While the extrinsic pathway of cell death is activated by intercellular ligands and 
involves signal transduction by a subset of TNF receptors and their associated factors, the 
intrinsic pathway leading to cell death is activated by numerous intracellular signals.  
Cellular stress, viral infection and DNA damage result in activation of pro-apoptotic 
members of the B-cell lymphoma-2 (BCL-2) family BCL-2 homology 3 (BH3)-only 
proteins (Youle and Strasser, 2008).  Activation of BH3-only proteins inhibits the 
activities of pro-survival members of the BCL-2 family (Willis et al., 2007), which in 
turn relieves the pro-apoptotic factors BCL-2 –antagonist/killer-1 (BAK) and BCL-2 –
associated X protein (BAX) (Cheng et al., 2001).  This results in the translocation of 
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BAX and BAK into the mitochondria and perturbation of the mitochondrial membranes, 
leading to release of mitochondrial resident pro-apoptotic molecules, including 
cytochrome c and second mitochondria-derived activator of caspase (Smac, DIABLO in 
mice) as shown in Figure 1.1 (Budihardjo et al., 1999; Du et al., 2000; Hao et al., 2005).  
Upon release into the cytosol, cytochrome c and Smac/DIABLO promote the activation 
of caspases by mechanisms discussed in more detail below (Du et al., 2000; Hao et al., 
2005; Srinivasula et al., 2000; Brustugun et al., 1998; Cain et al., 1999). 
Although the DISC is a central component of the Fas-mediated extrinsic pathway, 
and functions to induce cell death by activating caspases, the DISC can also promote cell 
death by activating components of the intrinsic pathway (Kuwana et al., 1998; Yin et al., 
1999).  The DISC promotes cleavage of the pro-apoptotic BH3-interacting domain death 
agonist (BID).  Cleavage of BID to truncated BID (tBID) subsequently results in the 
derepression of BAK and BAX, activating the intrinsic pathway as outlined in the 
previous paragraph and shown in Figure 1.1 (Kuwana et al., 1998; Cheng et al., 2001; Li 
et al., 1998).  
Central to the execution of cell death by both the extrinsic and the intrinsic 
apoptotic pathways, is the activity of caspases.  Caspases are cysteine proteases that 
predominantly cleave their substrates after an aspartate residue within their target (Lavrik 
et al., 2005). Caspases are encoded as zymogen molecules, and proteolytic cleavage of 
the zymogen produces an enzymatically active caspase.  The ced-3 gene identified by 
Ellis and Horvitz was the first gene found to encode a caspase protein.  However, 
caspases are evolutionarily conserved, and 14 mammalian caspases have since been 
identified (Stennicke and Salvesen, 1998; Nicholson, 1999; Budihardjo et al., 1999; Shi, 
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2004).  Although subsequent biochemical analysis has shown that not all identified 
caspases have pro-apoptotic functions, the discussion below is limited to the activities of 







Figure 1.1: The extrinsic and intrinsic apoptotic pathways.  The extrinsic apoptotic pathway is 
initiated by intercellular signals that activate a subset of pro-apoptotic TNF receptors, including 
the Fas receptor.  Activation of Fas receptor results in the recruitment and activation of caspase-8 
through the death-inducing signaling complex (DISC).  Caspase-8 subsequently activates 
caspase-3.  The intrinsic apoptotic pathway is initiated by intracellular insults such as 
chemotherapy or ultraviolet (UV) damage.  Activation of the intrinsic pathway involves 
derepression and translocation of Bax or Bak, which triggers the release of cytochrome c and 
Smac/DIABLO from the mitochondria.  Caspase-9 oligomerizes with Apaf-1, cytochrome c, and 
ATP to form the apoptosome, which activates caspase-9.  Smac/DIABLO antagonizes IAP 
proteins, which function to inhibit caspases, thereby freeing caspases from IAP proteins.  
Caspase-3 is subsequently activated by caspase-9.  Inhibitors of apoptosis (IAP) proteins are the 
most well described direct and indirect inhibitors of caspases and cell death. 
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Two subsets of caspases, initiator/apical caspases and effector/executioner 
caspases, have distinct temporal and spatial roles in the cell death pathway.  Activation of 
caspases occurs in a hierarchical manner, whereby initiator caspases are activated first, 
and executioner caspases are sequentially cleaved by activated initiator caspases (Shi, 
2002; Shi, 2004; Thornberry and Lazebnik, 1998).  In mammals, caspase-8 and caspase-9 
are the primary initiator caspases for the extrinsic and intrinsic pathways, respectively.  
Activation of caspase-8, occurs when this protein is recruited to the DISC, where the 
close proximity between caspase-8 molecules is thought to result in their enzymatic 
activation (Salvesen and Dixit, 1999; Medema et al., 1997; Chinnaiyan et al., 1995; 
Varfolomeev et al., 1998).  Caspase-9 activation occurs in a slightly more complex 
fashion, through the formation of a holoenzyme, known as the apoptosome, that also 
includes an adaptor molecule, apoptotic protease-activating factor 1 (Apaf-1), 
cytochrome c, and ATP.  The formation of the apoptosome is driven by the release of 
cytochrome c into the cytosol from the mitochondria.  Association of procaspase-9 with 
this protein complex promotes oligomerization of procaspase-9, which produces active 
caspase-9 (Acehan et al., 2002; Zou et al., 1999; Cain et al., 2000; Cain et al., 1999; 
Rodriguez and Lazebnik, 1999). 
Caspase-3 and caspase-7 are effector caspases common to both the intrinsic and 
extrinsic pathway.  Once caspase-8 or caspase-9 has been activated, downstream 
executioner caspases, such as caspase-3 and -7, can be targeted and activated through 
cleavage by activated initiator caspases.  Activation of executioner caspases ultimately 
lead to the gross morphological changes that characterize apoptosis, including DNA 
fragmentation and dissociation of the cytoskeletal structure.  Executioner caspases have 
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diverse substrates with unique functions and their cleavage collectively compromise the 
integrity of the cell.  For example, poly(ADP-ribose) polymerase (PARP), which is 
abundantly present in the nucleus and catalyzes poly(ADP-ribose) ligation following 
DNA strand breaks, is a substrate of caspase-3 and -7.  Caspase-3 and -7 cleave PARP, 
which prevents ADP-ribose polymer synthesis in response to DNA damage (Kang et al., 
2004).  Additionally, cleavage by caspase-3 of the chaperone/inhibitor protein, inhibitor 
of caspase-activated deoxyribonuclease (ICAD), releases the nuclease, caspase-activated 
deoxyribonuclease (CAD), which is responsible for cleaving double-stranded DNA into 
oligonucleosomal fragments (Enari et al., 1998). 
 
Inhibitors of Apoptosis 
 
While there are many cellular insults and stimuli that activate cell death pathways, 
it was discovered that cells retain an intricate regulatory mechanism to control induction 
and execution of cell death.  This is especially important, as unchecked cell death could 
be detrimental to the proper functioning of a complex multicellular organism (Salvesen 
and Duckett, 2002).  Thus, it is not surprising that caspases are normally present in the 
inactive zymogen form.  However, beyond regulating the activities of pro-apoptotic 
molecules such as caspases, it was hypothesized that the relative expression of effectors 
and regulators of cell death might also regulate the induction and execution of cell death.  
Thus, a cell that has acquired DNA damage or undergone cell cycle arrest might have an 
altered apoptotic threshold based on the presence and activity levels of apoptotic effectors 
and regulatory proteins, which would allow a damaged or stressed cell the ability to 
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recover, if cellular mechanisms exist to repair the damage or properly remove the insult.  
Based on this hypothesis, the stoichiometry of active pro- and anti-apoptotic molecules 
would also be a critical factor in determining the apoptotic threshold, and the activation 
of pro-apoptotic molecules might not be sufficient to induce and/or execute apoptosis 
(Salvesen and Duckett, 2002). 
Supporting the hypothesis that cellular mechanisms exist to regulate the induction 
and execution of cell death, two major classes of anti-apoptotic proteins were identified, 
the BCL-2 protein family (introduced previously) and the inhibitor of apoptosis (IAP) 
protein family (Youle and Strasser, 2008; Salvesen and Duckett, 2002; Srinivasula and 
Ashwell, 2008).  Members of these two protein families can regulate cell death through 
distinct mechanisms, and due to the context of this dissertation, the BCL-2 pro-survival 
family will only be discussed briefly.   
The BCL-2 family, as reviewed by Youle & Strasser, contains at least 14 
mammalian pro- and anti-apoptotic proteins that regulate cell death.  There are five pro-
survival BCL-2 family members, including BCL-2 and BCL-XL, that function to repress 
the activities of pro-apoptotic BCL-2 family members, BAX and BAK, which in turn are 
capable of perturbing the outer mitochondrial membrane, as described above.  Therefore, 
suppression of apoptosis by BCL-2 members occurs relatively early in the cell death 
signaling cascade, prior to formation of the apoptosome or activation of caspases (Youle 
and Strasser, 2008).  
In 1993, Miller and colleagues identified a baculoviral gene, inhibitor of apoptosis 
(iap) that was capable of preventing cell death of infected insect cells (Crook et al., 
1993).  The observation that this viral gene encoded a protein that could inhibit apoptosis 
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supported that the intracellular mechanisms to achieve cell death are very tightly 
regulated, and that cellular insults might not always result in cell death, depending on the 
expression levels of cell death inhibitors.  Following the identification of the baculovirus 
iap gene, iap genes were found to be highly conserved and present in the genomes of 
yeast, nematodes, fruit flies, mice, and humans (Duckett et al., 1996; Liston et al., 1996; 
Roy et al., 1995; Uren et al., 1996; Rothe et al., 1995a; Hay et al., 1995; Fraser et al., 
1999; Uren et al., 1999).  To date, eight mammalian IAP proteins have been identified 
(Figure 1.2).  The best characterized of the mammalian IAP proteins are X-linked IAP 
(XIAP), cellular IAP 1 (c-IAP1) and cellular IAP 2 (c-IAP2). 
 
Figure 1.2: Schematic representation of mammalian Inhibitor of Apoptosis (IAP) proteins.  
BIR; baculovirus IAP repeat; CARD; caspase-recruitment domain; RING finger; really 
interesting new gene finger. 
 
Inclusion in the IAP family is determined by the presence of a conserved ~70 
amino acid zinc binding motif, the baculoviral IAP repeat (BIR) domain (Miller, 1999; 
Hinds et al., 1999; Sun et al., 1999).  Each IAP protein has at least one BIR domain, and 
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many IAP proteins have two or three BIR domains in tandem at the amino-terminal 
region of the protein.  The signature sequence in BIR domains CX2CX16HX6C (C = 
cysteine, H = histidine, X = any amino acid) coordinates a zinc ion at the core of the three 
β sheets formed by the BIR sequence (Hinds et al., 1999; Sun et al., 2000; Sun et al., 
1999; Verdecia et al., 2000).   
The principal function of the BIR domains in IAP proteins is to mediate protein-
protein interactions.  For example, the BIR2 domain region of XIAP coordinates 
interactions between XIAP and caspase-3, caspase-7, as well as another pro-apoptotic 
molecule released from the mitochondria, apoptosis-inducing factor (AIF) (Eckelman et 
al., 2006; Wilkinson et al., 2008).  Meanwhile, BIR1 within c-IAP1 coordinates the 
association of c-IAP1 with the TNF signaling adaptor molecule, TNF-receptor-associated 
factor-2 (TRAF2) through the PXXER motif (P = proline, E = glutamic acid, and R = 
arginine) (Samuel et al., 2006; Varfolomeev et al., 2007).  Interestingly, a correlation was 
noted between the number of BIR domains present in an IAP protein, and the affinity of 
that IAP protein for a given interaction partner or the number of potential interaction 
partners (Srinivasula and Ashwell, 2008).  As the number of BIR domains increases, the 
affinity for associated proteins increases and/or the number of potential binding partners 
increases.  
Although the presence of a BIR domain is the defining structural characteristic of 
an IAP protein, many IAP proteins contain additional domains.  A really interesting new 
gene (RING) domain is present at the carboxy-termini of several IAP proteins, including 
XIAP, c-IAP1 and c-IAP2.  The RING domains in IAP proteins are zinc-binding motifs 
contain six to seven cysteines and one or two histidines, which coordinate the binding of 
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two zinc ions to the RING domain (Joazeiro and Weissman, 2000).  RING domains 
harbor E3 ubiquitin ligase activity that catalyzes the ubiquitination and degradation of 
target proteins through a sequential enzymatic reaction that also involves an ubiquitin 
activating enzyme (E1) and an ubiquitin conjugating enzyme (E2) (Joazeiro and 
Weissman, 2000; Lorick et al., 1999; Weissman, 2001).  IAP proteins can undergo 
autoubiquitination and several targets of ubiquitination by IAP proteins have also been 
reported (Dohi et al., 2004; Conze et al., 2005; Silke et al., 2005).  The role of 
ubiquitination in IAP protein stability and the consequences of interactions with 
intracellular signaling molecules is currently a major area of research. 
Finally, c-IAP1 and c-IAP2 also contain a caspase-associated recruitment domain 
(CARD).  The single CARD present in both c-IAP1 and c-IAP2 is located between the 
BIR3 and RING domains.  CARDs are generally thought to function in 
heterodimerization between adaptor molecules and procaspases.  However, the CARDs 
of c-IAP1 and c-IAP2 have not been as fully characterized as the BIR and RING 
domains, and the functions are currently unknown (Verhagen et al., 2001). 
 
Anti-Apoptotic Functions of IAP Proteins 
 
Since the discovery in 1993 that the presence of the baculoviral gene iap inhibited 
cell death in infected insect cells tremendous efforts have been made to determine the 
mechanisms by which IAP proteins protect against cell death.  Presently, a significant 
collection of structural, biochemical, and in vivo research from numerous laboratories 
provides great insight into how different IAP proteins inhibit apoptosis (Shi, 2004).  In 
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the current functional model, there are several mechanisms, both caspase-dependent and 
caspase-independent, that IAP proteins utilize to inhibit cell death. 
XIAP is the prototypical IAP protein that binds directly to caspases through its 
BIR domains and inhibits the enzymatic activities of several caspases, including caspase-
3, -7, and -9 (Eckelman et al., 2006; Shiozaki and Shi, 2004; Takahashi et al., 1998).  
Because of its ability to directly inhibit several chief caspases, XIAP is considered a 
potent cell death inhibitor.  XIAP protective activitiy against cell death was found to be 
over 1000 fold greater than that of c-IAP1 or c-IAP2 (Deveraux et al., 1998).   
Whereas XIAP binds to and inhibits the enzymatic activities of several caspases, 
c-IAP1 and c-IAP2 have subsequently been shown to bind to but not inhibit the 
enzymatic activities of caspases (Eckelman and Salvesen, 2006).  Therefore, it was 
hypothesized that c-IAP1 and c-IAP2 might instead function to inhibit cell death by 
alternative mechanisms.  The prototypical baculoviral IAP expressed by Orgyia 
pseudotsugata nucleopolyhedrosis virus (OpMNPV, termed OpIAP) was also found to be 
incapable of binding all tested caspases, but still inhibited cell death (Wilkinson et al., 
2004; Wright and Clem, 2001).  These findings supported the hypothesis that not all IAP 
proteins protect against cell death by directly inhibiting caspases. 
Subsequent to the discoveries that several IAP proteins did not inhibit the 
enzymatic functions of caspases, but could still provide protection against cell death, 
biochemical studies identified IAP interacting proteins, second mitochondrial activator of 
caspases (Smac) in humans and direct IAP binding protein with low pI (DIABLO) in 
mice (Du et al., 2000; Verhagen et al., 2000).  Smac/DIABLO is a 239 amino acid 
protein that is nuclear encoded, and contains a 55 amino acid mitochondrial localization 
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signal (MLS) at its amino-terminus.  Therefore, Smac/DIABLO is shuttled into the inter-
membrane space of the mitochondria after translation.  Upon arrival in the mitochondria, 
the MLS is cleaved from Smac/DIABLO, revealing an IAP-binding motif (IBM) at the 
amino-terminus. The IBM of Smac/DIABLO is an evolutionarily conserved tetrapeptide 
also present in Drosophila melanogaster orthologs of Smac/DIABLO (Wing et al., 2001; 
Wright and Clem, 2001; Wu et al., 2001). 
As described earlier, following perturbation of mitochondria induced by cellular 
stress or damage, mature Smac/DIABLO is released into the cytosol, along with 
cytochrome c, where it functions as a direct IAP inhibitor by binding to IAP proteins 
through the IBM motif (Vaux and Silke, 2003; Yang and Du, 2004).  Therefore, 
Smac/DIABLO functions to negatively regulate the inhibitory properties of IAP proteins 
by displacing IAP proteins bound to caspases, freeing caspases to become activated, and 
targeting IAP proteins for ubiquitination and proteasome-mediated degradation (Liu et 
al., 2000; Wu et al., 2000; Srinivasula et al., 2000; Srinivasula et al., 2001; Chai et al., 
2000).  Since its identification, Smac/DIABLO has been shown to associate with several 
IAP proteins, including XIAP, c-IAP1, c-IAP2, and OpIAP (Yang and Du, 2004; 
Wilkinson et al., 2004; Liu et al., 2000; Wu et al., 2000).  Mutation or deletion of residue 
one of the IBM motif, alanine, abrogates binding of Smac/DIABLO to IAP proteins and 
prevents caspase-3 activation (Liu et al., 2000; Wu et al., 2000).  In addition to the direct 
inhibitory activity of Smac/DIABLO it has been shown that Smac/DIABLO can induce 
the autoubiquitination of several IAP proteins.  However, the converse has also been 
observed, and XIAP, c-IAP1 and c-IAP2 have all been shown to target Smac/DIABLO 
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for ubiquitination and proteasome-mediated degradation (MacFarlane et al., 2002; Hu 
and Yang, 2003).   
Given that Smac/DIABLO associates with several IAP proteins that do not bind to 
or inhibit the activities of caspases, it has been proposed that these IAP proteins function 
to sequester mature Smac/DIABLO after release from the mitochondria.  Sequestering 
Smac/DIABLO may serve as a regulatory mechanism to allow damaged cells to recover, 
even when pro-apoptotic proteins have been released or activated, and signifies a 
dynamic regulatory process.  It remains to be tested whether by preventing 
Smac/DIABLO from antagonizing direct caspase inhibitors such as XIAP these other 
IAP proteins are displaying an alternative mechanism of cellular protection through 
sequestration and saturation of mature Smac/DIABLO. 
Surprisingly, given its negative regulatory effects on IAP proteins, Smac-deficient 
cells did not display significant defects in cell death when challenged with apoptotic 
stimuli (Okada et al., 2002).  A splice variant of Smac has also been identified that lacks 
the IBM and is localized to the cytosol (Roberts et al., 2001).  Although this variant of 
Smac lacks the IBM, it can still potentiate cell death.  This finding suggests that although 
full-length Smac/DIABLO functions to negatively regulate IAP proteins through the 
IBM, other regions of Smac/DIABLO might serve important cellular functions.  One 
such possibility is that the interaction between Smac/DIABLO and IAP proteins could 
alter the function of IAP proteins in alternative signaling pathways, since it has now been 
well established that several IAP proteins, including c-IAP1 and c-IAP2, function in 
additional or alternative pathways (Rothe et al., 1995a; Srinivasula and Ashwell, 2008). 
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Non-Apoptotic Functions of IAP Proteins 
 
While many IAP proteins have been shown to function to inhibit cell death, not 
all members of the IAP family inhibit apoptosis (Srinivasula and Ashwell, 2008; 
Verhagen et al., 2001).  Several IAP proteins are instead referred to as BIR-containing 
proteins (BIRPs), because although they contain the signature IAP domain, they do not 
protect against cell death (Srinivasula and Ashwell, 2008; Verhagen et al., 2001).  These 
IAP/BIRPs are present in yeast and C. elegans, and instead function in alternative cellular 
processes, such as cell division or cytokinesis (Fraser et al., 1999).   
Furthermore, as reviewed extensively by Srinivasula and Ashwell, it is now clear 
that many members of the IAP family that can function as cell death inhibitors are critical 
to additional, non-apoptotic signaling pathways.  While these proteins were categorized 
in the IAP family because they contain the signature BIR domain and their given name 
implies that their primary function is to protect against death-inducing stimuli, an 
increasing number of IAP proteins play critical roles in additional intracellular pathways, 
many of which are unrelated to apoptosis.  IAP proteins have now been shown to 
function in copper homeostasis, cell division, innate immunity, and other intracellular 
signaling pathways (Burstein et al., 2004; Srinivasula and Ashwell, 2008; Conte et al., 
2006; Varfolomeev et al., 2007; Vince et al., 2007; Tang et al., 2003; Petersen et al., 
2007; Altieri, 2003). 
The potent apoptosis suppressor, XIAP, has been shown to function in additional 
signaling pathways.  Burstein et al. discovered that XIAP functions in copper 
homeostasis, when XIAP was found to associate with copper metabolism gene MURR1 
17 
domain containing 1 (COMMD1), a factor required for proper copper excretion.  XIAP 
was subsequently shown to target COMMD1 for ubiquitination and degradation, 
resulting in a predicted increase in intracellular copper levels.  Although it was found that 
BIR3 of XIAP mediated the interaction between XIAP and COMMD1, the E3 ubiquitin 
ligase activity in the RING domain in XIAP was found to catalyze the ubiquitination and 
proteasomal degradation of COMMD1 (Burstein et al., 2004). 
The cellular IAP proteins, c-IAP1 and c-IAP2, were identified in a biochemical 
screen for type-2 TNF receptor (TNFR2) associated proteins (Rothe et al., 1995a).  The 
association of c-IAP1 and c-IAP2 with TNFR2 was found to be mediated by the TNF 
receptor associated factors 1 and 2 (TRAF1 and TRAF2) .  The interaction between c-
IAP1/2 and TRAF2, as noted previously, is mediated by BIR1 in c-IAP1/2 (Samuel et al., 
2006).  However, at the time of the discovery that c-IAP1 and TRAF2 associate, the 
consequence of this association was thought to only affect transcriptional activation, not 
inhibition of apoptosis, since activation of TNFR2 regulates induction of nuclear factor-
κB (NF-κB) transcription factors (Li et al., 2002; Rothe et al., 1995a; Rothe et al., 
1995b).   
NF-κB activation is critical for immune responses, cell survival and proliferation, 
and has been extensively reviewed by Hayden and Ghosh.  NF-κB subunits are normally 
sequestered in the cytosol but upon a variety of stimuli, including ligation of TNF 
receptor family members, NF-κB subunits can translocate into the nucleus and activate 
transcription of NF-κB responsive genes.  Two major NF-κB activation pathways have 
been described, the canonical and the alternative pathway (Figure 1.3).  In the canonical 
pathway, phosphorylation and subsequent degradation of inhibitors of NF-κB (IκBs) 
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leads to translocation of NF-κB subunits into the nucleus.  In the alternative pathway, 
following activation of NF-κB inducing kinase (NIK), p100/NF-κB2 is proteolytically 
processed to p52, which translocates into the nucleus (Hayden and Ghosh, 2004; Hayden 
et al., 2006; Hayden and Ghosh, 2008). 
While the TRAF2-c-IAP1/2 interaction was identified over a decade ago, the 
precise role of this complex in TNF signaling has remained unclear.  Initial reports 
suggested that c-IAP1 might have a pro-apoptotic role in TNFR2 signaling by targeting 
TRAF2 for ubiquitination and degradation following TNFR2 activation by TNF (Li et al., 
2002).  Given the prior finding that TRAF2 mediates NF-κB activation by TNF receptors 
(Rothe et al., 1995b), it was also hypothesized that c-IAP1 might alternatively be 
targeting other NF-κB regulatory molecules, including the DD-containing 
serine/threonine kinase, receptor interacting protein kinase 1 (RIP1), NF-κB essential 
modulator (NEMO), or NIK.  Furthermore, the consequences of the interaction between 
TRAF2 and c-IAP1 on c-IAP1 stability currently remain unclear.  However, given that 
the RING domains of TRAF proteins have been found to modulate protein stability by 
ubiquitination, and association of c-IAP1 with TRAF2 might also redirect the 
autoubiquitination properties of c-IAP1, this association might be critical to 
understanding how c-IAP1 functions in apoptotic and non-apoptotic signaling cascades. 
 
IAP Proteins & Cancer 
 
The evasion of apoptosis has been shown to be a hallmark of tumorigenesis, and 
many cancer therapy strategies, including chemotherapy, function by inducing apoptosis 
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of cancer cells (Brown and Attardi, 2005).  Because several IAP proteins were found to 
be oncogenic and highly expressed in numerous neoplasms, it was thought that IAP 
proteins might confer resistance to apoptotic induction for cancer cells by inhibiting 
caspase activity (Fulda, 2007; Zender et al., 2006; Hunter et al., 2007; Altieri, 2003; 
Duffy et al., 2007).  Therefore, as described by Wright and Duckett, several labs pursued 
designing compounds to target cancer cells to undergo apoptosis.  Specifically, RNA 
interference and antagonist compounds were designed to target several pro-survival 
molecules, including specific IAP proteins and anti-apoptotic BCL-2 family members 
(Wright and Duckett, 2005).  Indeed, anti-sense oligonucleotides directed against XIAP 
can sensitize cancer cells to chemotherapy and ligand-induced death, and currently there 
are a host of IAP inhibitors that are in clinical trials (Fulda, 2007; Hunter et al., 2007; 
LaCasse et al., 2006; Cummings et al., 2006).   
Although several IAP proteins were observed to be highly expressed in forms of 
neoplasia, a signature chromosomal translocation involving the gene that encodes c-IAP2 
also occurs in at least 33% of extranodal marginal zone B-cell lymphoma of mucosa-
associated lymphoid tissue (MALT lymphomas).  MALT lymphomas usually arise in the 
stomach in the context of chronic Helicobacter pylori infections.  A fusion protein 
between the amino-terminal region of c-IAP2 and the carboxy-terminal region of mucosa 
associated lymphoid tissue lymphoma translocation gene 1 (MALT1) is typically 
observed (Dierlamm et al., 1999; Uren et al., 2000).  This translocation event is 
associated with a more aggressive tumor that does not respond to H. pylori eradication.  
The fusion protein is a potent activator of NF-κB by inducing self-oligomerization and 
increasing the E3 ubiquitin ligase activity of MALT1 on NEMO, resulting in IKK 
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activation (Varfolomeev et al., 2006; Zhou et al., 2005).   The MALT1 portion of the c-
IAP2/MALT1 fusion was shown to trigger the cleavage of A20, a deubiquitinating 
enzyme that is an inhibitor of NEMO, thus promoting NF-κB activation (Coornaert et al., 
2008).  Therefore, this finding supported the idea that IAP proteins might be supporting 
tumorigenesis by alternative or additional mechanisms beyond inhibition of cell death, 
however many possibilities are currently untested. 
Figure 1.3: Activation of the canonical and alternative NF-κB pathways by TNF receptors.   
In the canonical NF-κB pathway, inhibitors of NF-κB (IκBs) are phosphorylated and degraded, 
freeing NF-κB subunits to translocate into the nucleus.  In the alternative NF-κB pathway, 
activation of NIK leads to processing of p100/NF-κB2 to p52, which translocates into the 
nucleus. *= phosphorylation 
 
An alternative to specific IAP targeted therapeutics was to design a compound 
that could interact with multiple IAP proteins.  Therefore, numerous laboratories and 
pharmaceutical companies have designed synthetic, which could recapitulate the binding 
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properties of mature Smac/DIABLO.  Several successful synthetic derivatives of 
Smac/DIABLO have been developed to target the IAP proteins and induce cell death by 
relieving IAP inhibition of caspases (Vucic and Fairbrother, 2007; Fischer and Schulze-
Osthoff, 2005).  Therefore, these tetrapeptide compounds were originally developed to 
promote apoptosis in cancer cells that may have elevated levels of IAP proteins, 
conferring a protective phenotype.  However, the cellular impact of these IAP antagonist 
is much more profound than previously expected, since it was originally hypothesized 
that IAP proteins solely functioned to protect against cell death by inhibiting caspase 
activities. Additional novel roles in intracellular signaling pathways have been identified 
which can modulate sensitivity to cell death stimuli (Varfolomeev et al., 2007; Vince et 




The goal of this dissertation was to characterize the cellular roles of c-IAP1 and 
its regulation by Smac/DIABLO or through signaling of TNF receptors.  I investigated 
how association of c-IAP1 with TRAF2 and Smac/DIABLO affected the stability of c-
IAP1, and the consequence of these events on cell death and NF-κB activation with the 
following specific aims: 
Specific Aim I (Chapter 2): Determine the mechanism of c-IAP1 stabilization by 
TRAF2, and identify the cytoprotective effects of TRAF2-stabilized c-IAP1. 
Specific Aim II (Chapter 3): Describe the two distinct signaling cascades that 
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Inhibitor of apoptosis (IAP) proteins are key regulators of intracellular signaling 
that interact with tumor necrosis factor (TNF) receptor superfamily members as well as 
pro-apoptotic molecules such as Smac/DIABLO and caspases.  While the X-linked IAP 
(XIAP) is an established caspase inhibitor, the protective mechanisms utilized by the 
cellular IAP (c-IAP) proteins are less clear, since c-IAPs bind to but do not inhibit the 
enzymatic activities of caspases.  In this study, c-IAPs are shown to be highly unstable 
molecules that undergo autoubiquitination.   The autoubiquitination of c-IAP1 is blocked 
upon association with TNF receptor-associated factor TRAF2, and this is achieved by 
inhibition of the E3 ubiquitin ligase activity intrinsic to the RING of c-IAP1.  Consistent 
with these observations, loss of TRAF2 results in a decrease in c-IAP1 levels.  Stabilized 
c-IAP1 was found to sequester and prevent Smac/DIABLO from antagonizing XIAP, and 
protect against cell death.  Therefore, this study describes an intriguing cytoprotective 
mechanism utilized by c-IAP1, and provides critical insight into how IAP proteins 




The Inhibitors of Apoptosis (IAPs) are an evolutionarily conserved gene family 
originally described as encoding cell death inhibitors.  IAP proteins have subsequently 
been found to participate in a variety of additional intracellular signaling processes 
(Srinivasula and Ashwell, 2008), and it has become evident that IAP proteins are 
versatile molecules playing numerous distinct roles within the cell.  While a more 
complete understanding of these additional functions for IAP proteins is emerging, the 
distinct mechanisms utilized by some IAP proteins to function in their originally defined 
roles as cell death inhibitors remain unclear.  
Members of the IAP family are characterized by the presence of one to three 
tandem repeats of an ~70 residue baculovirus IAP repeat (BIR) domain (Eckelman and 
Salvesen, 2006).  The BIR domains of many IAP proteins have been shown to be the 
region within IAP proteins that associates with caspases and other pro-apoptotic 
molecules (Sun et al., 1999; Deveraux et al., 1999).  IAP proteins have remarkably 
different apoptotic inhibitory abilities.  For example, X-linked IAP (XIAP) is a highly 
potent cell death inhibitor (Deveraux and Reed, 1999), and is thought to be the only 
mammalian IAP protein that directly inhibits the enzymatic activities of caspases 
(Eckelman and Salvesen, 2006; Sun et al., 1999; Deveraux et al., 1999; Tenev et al., 
2004).  While cellular IAP1 and 2 (c-IAP1 and c-IAP2) are anti-apoptotic proteins that 
can bind to caspase-7 and -9, they do not inhibit the enzymatic activities of these caspases 
(Eckelman and Salvesen, 2006; Tenev et al., 2004).   
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Many IAP proteins, including c-IAP1 and c-IAP2, contain a carboxy-terminal 
RING domain that can function as an E3 ubiquitin ligase (Yang et al., 2000).  The E3 
ubiquitin ligase activity of the RING domain in c-IAP1 and c-IAP2 was previously 
shown to negatively regulate the apoptotic inhibitory properties of the c-IAP proteins, 
and to promote autoubiquitination and degradation of c-IAP1 (Clem et al., 2001; Yang 
and Du, 2004), thus hindering attempts to define the cellular properties of this protein. 
A specialized property of the c-IAP proteins is their involvement in tumor 
necrosis family (TNF) signaling (Shu et al., 1996; Rothe et al., 1995a; Li et al., 2002).  
Both c-IAP1 and c-IAP2 were discovered in a biochemical screen for factors associated 
with the type-2 TNF receptor (TNFR2).  This association was found to be indirect and 
bridged by interactions with TNF receptor-associated factors (TRAFs), most notably 
TRAF1 and TRAF2 (Rothe et al., 1995a).  Though the consequences of the association 
between TRAF2 and c-IAP1 on TNF-mediated signaling have been investigated (Li et 
al., 2002), less is known about the functional significance of the association between 
TRAF2 and c-IAP1 on cell death inhibition.  Since both c-IAP1 and TRAF2 possess E3 
ubiquitin ligase activity in their respective RING domains, it seemed that the association 
between these molecules might impact the protective properties of c-IAP1 and alter the 
apoptotic threshold. 
In this study, the role of TRAF2 in c-IAP1 stability and how the association of 
TRAF2 with c-IAP1 affects the apoptotic inhibitory properties of c-IAP1 were examined.  
The presence of TRAF2 greatly enhanced the stability of c-IAP1, and these data suggest 
that the interaction between TRAF2 and c-IAP1 inhibits the E3 ubiquitin ligase activity 
intrinsic to the RING domain of c-IAP1.  Using stabilized c-IAP1, the anti-apoptotic 
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activity of c-IAP1 was characterized, and it was found that c-IAP1 suppresses apoptosis 
to a degree comparable to XIAP.  Furthermore, we show that c-IAP1 functions to prevent 
the IAP antagonist, Smac/DIABLO (Du et al., 2000; Verhagen et al., 2000), from 
interfering with XIAP inhibition of caspases.  Together, this study demonstrates that 
although c-IAP1 does not directly inhibit caspase activity, stabilized c-IAP1 can 
sequester Smac/DIABLO, prevent Smac/DIABLO from antagonizing XIAP, and inhibit 




Materials: Reagents were obtained from the following sources: MG-132 (Sigma), 
protein G-coupled agarose, L-glutamine, and PBS (Invitrogen), DMSO (Sigma Aldrich), 
Dulbecco's modified Eagle's medium and fetal bovine serum (Mediatech), siRNA 
oligonucleotides (Xeragon/Qiagen), Caspase assay kit (BIOSOURCE), DEVD-AFC 
(BioMol), protease inhibitor mixture tablets (Complete mini) (Roche), and QuikChange 
site-directed mutagenesis kit (Stratagene).  Dr. Tak Mak (University of Toronto) kindly 
provided TRAF2-deficient MEFs (Yeh et al., 1997).  Antibodies were obtained from the 
following sources: HA (Covance), β-actin and peroxidase conjugated anti-HA (Sigma), 
TRAF2 (BD Pharmingen), XIAP (BD Transduction), and Smac/DIABLO (Calbiochem), 
peroxidase conjugated anti-mouse, anti-rabbit, and anti-rat (GE Healthcare).  Dr. John 
Silke (La Trobe University, Melbourne) kindly provided anti-c-IAP1 (Vince et al., 2007). 
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Plasmids: pEBB HA-c-IAP1 and pEBB HA-c-IAP2 were subcloned from pEBG c-IAP1 
and pEBG c-IAP2, respectively (Duckett et al., 1998).  Site-directed mutagenesis of c-
IAP1 and c-IAP2 to generate c-IAP1 H588A and c-IAP2 H574A was performed using 
the QuikChange site-directed mutagenesis kit (Stratagene).  Unless otherwise noted, 
plasmids and siRNA oligonucleotides used for this study have been described previously 
(Duckett et al., 1998; Duckett and Thompson, 1997; Wilkinson et al., 2004). 
 
Cell Culture, Transfections and MG-132 Treatment: HEK293 cells and MEFs were 
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine 
serum and 2 mM L-glutamine and maintained at 37 ˚C in an atmosphere of 95% air, 5% 
CO2.  Cells were transfected with plasmids and siRNA oligonucleotides using a standard 
calcium phosphate transfection protocol.  HEK293 cells were treated with 35 µM MG-
132 for 4 hours.  Following treatment with MG-132, cells were harvested and 
immunoblot analysis was carried out as described below. 
 
Caspase Activity Assays:  Adherent and floating cells were harvested and caspase-3 
assays were performed using the Caspase assay kit (BIOSOURCE) according to the 
manufacturer's instructions.  AFC released was measured overtime at 37 ˚C using a 
Cytoflour 4000 multi-well plate reader (Applied Biosystems).  A total of 20 
measurements at 90-sec intervals were taken for AFC release with an excitation 
wavelength = 400 nm and an emission wavelength = 508 nm. 
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Cell Lysate Preparation and Immunoblot Analysis:  Cell lysates were prepared with 
RIPA lysis buffer (PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
SDS) supplemented with protease inhibitors, for 30 min on ice to ensure complete lysis 
unless noted otherwise.  Protein quantification was determined by Bradford assay (Bio-
Rad). RIPA cell lysates of equal protein concentrations were prepared in LDS sample 
buffer, separated on denaturing NuPAGE 4-12% polyacrylamide gradient gels, and 
transferred to 0.45 µm nitrocellulose membranes (Invitrogen).  Membranes were blocked 
in 5% milk in Tris buffered saline (TBS) with 0.02 - 0.2% Tween 20 (Bio-Rad) 
depending on the antibody requirements, followed by incubation with the indicated 
antibodies in 2.5% milk for 1 hour at room temperature or overnight at 4 ˚C.  After 
washing with TBS containing 0.02 - 0.2% Tween, membranes were incubated with 
secondary antibodies for 1 hour at room temperature.  Enhanced chemiluminescence (GE 
Healthcare) was used to visualize the blots on Kodak XAR film. 
 
Immunoprecipitations: Cell lysates were prepared in RIPA lysis buffer, normalized for 
protein content, and incubated with HA or XIAP antibodies for 2 hours at 4 ˚C.  Protein 
G-coupled agarose beads were then added to the lysates and incubated for an additional 1 
hour.  Centrifugation was performed to recover agarose beads, followed by washing in 
RIPA lysis buffer.  Precipitated proteins were eluted by adding LDS sample buffer 
(Invitrogen) and heating the samples for 10 min at 95 ˚C.  Recovered proteins were 




Real Time Reverse Transcription-PCR: HEK293 cells were transfected with plasmids, 
and twenty-four hours following transfection total RNA was isolated using the RNeasy 
minikit (Qiagen) according to the manufacturer's instructions.  Reverse transcription with 
random hexamer primers and MultiScribeTM Reverse Transcriptase (Applied Biosystems) 
was performed on 100 ng of total RNA.  The indicated target assays were performed on 1 
µL of resulting cDNA.  Each target assay was performed in triplicate and normalized to 




c-IAP1 levels are reduced in TRAF2-deficient cells 
Previous studies have shown that the cellular signaling regulators, c-IAP1 and c-
IAP2, can interact with TNF receptor superfamily members, and that an association with 
TRAF proteins, primarily TRAF1 and TRAF2, mediates this interaction (Li et al., 2002; 
Rothe et al., 1995a; Shu et al., 1996).  Although the interaction between c-IAP1 and 
TRAF2 was subsequently described to result in c-IAP1-mediated ubiquitination and 
degradation of TRAF2 (Li et al., 2002), less is known about the functional consequences 




Figure 2.1:  Reduction of c-IAP1 in TRAF2-deficient cells.  (A) TRAF2-deficient MEFs were 
harvested and immunoblot analysis was performed for endogenous TRAF2, c-IAP1 and XIAP.  
The asterisk indicates a nonspecific protein recognized by the TRAF2 antibody.  (B) HEK293 
cells were transfected with double-stranded scrambled siRNA oligonucleotides or two different 
siRNA oligonucleotides targeting TRAF2.  Forty-eight hours following transfection, cells were 
harvested and immunoblot analysis was performed for endogenous TRAF2, c-IAP1 and XIAP.  
Equivalent protein loading was confirmed in A and B by immunoblotting for β-actin. 
 
To further characterize the interaction between c-IAP1 and TRAF2, we examined 
how loss of TRAF2 might affect c-IAP1 expression.  Interestingly, in TRAF2-deficient 
murine embryonic-derived fibroblasts (MEFs) a notable and specific reduction in 
endogenous c-IAP1 protein levels was observed, while levels of other proteins, including 
XIAP, remained unchanged (Figure 2.1A).  This finding suggested that TRAF2 might 
play a role in the regulation of c-IAP1 protein levels. 
 
Given the observed reduction in endogenous c-IAP1 protein levels in TRAF2-
deficient fibroblasts, we sought to determine whether a reduction of TRAF2 in human 
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cells would affect c-IAP1 using an RNA interference (RNAi) approach.  Two small 
interfering RNA (siRNA) oligonucleotides for TRAF2 were used individually or in 
combination to suppress TRAF2 protein levels in human embryonic kidney (HEK) 293 
cells (Figure 2.1B).  Examination of c-IAP1 protein levels in the TRAF2 suppressed 
HEK293 cells revealed also a reduction in endogenous c-IAP1 levels.  Similarly, other 
IAP proteins, such as XIAP, were unaffected by a reduction in TRAF2 levels (Figure 
2.1B).  These data suggest that the interaction between c-IAP1 and TRAF2 alters the 
regulation of c-IAP1 protein levels. 
 
c-IAP1 and c-IAP2 undergo continuous basal autoubiquitination 
Since the stability of c-IAP1 appeared to be dependent on TRAF2, we sought to 
compare the relative expression levels of several IAP proteins.  Plasmids encoding XIAP, 
c-IAP1 and c-IAP2 with the same parental vector and epitope tag with no extraneous 5' or 
3' sequences were transfected into HEK293 cells.  Upon examination of cell lysates 
normalized for protein content, XIAP expression was consistently found to be 
significantly greater than c-IAP1 or c-IAP2 expression (Figure 2.2A), suggesting that c-
IAP1 and c-IAP2 were unstable proteins. 
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Figure 2.2:  c-IAP proteins undergo autoubiquitination mediated by their RING domains.  
(A) HEK293 cells were transfected with amino-terminally HA epitope tagged c-IAP1, c-IAP2 
and XIAP.  Twenty-four hours following transfection, cells were lysed and immunoblotted for 
HA (c-IAP1, c-IAP2 and XIAP).  (B) HEK293 cells were transfected with plasmids encoding 
HA-c-IAP1 and HA-c-IAP2.  Eighteen hours after transfection, cells were left untreated or treated 
with 35 µM MG-132 for 4 hours.  Following treatment with MG-132, cells were harvested and 
immunoblotted for HA (c-IAP1, c-IAP2, and XIAP).  (C) Site-directed mutagenesis was 
performed to convert the coding sequence corresponding to histidine residues 588 in c-IAP1, 574 
in c-IAP2, and 467 in XIAP located within the RING domains of these IAP proteins to alanines in 
order to generate E3 ubiquitin ligase deficient proteins.  HEK293 cells were then transfected with 
plasmids encoding HA-c-IAP1, HA-c-IAP2, and HA-XIAP, or the corresponding HA-tagged 
RING mutants.  Twenty-four hours following transfection, cell lysates were prepared and 
immunoblot analysis was performed.  Equivalent protein loading was verified in A, B and C by 
immunoblotting for β-actin. 
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Since c-IAP1 and c-IAP2 were poorly expressed under these conditions, we 
examined whether these proteins were undergoing ubiquitination and proteasome-
mediated degradation.  HEK293 cells were treated with MG-132 to inhibit proteasomal 
activity, and to determine if the c-IAP proteins undergo ubiquitination and degradation.  
c-IAP1 and c-IAP2 protein levels were increased after MG-132 treatment in comparison 
to untreated cells that were transfected with c-IAP1 or c-IAP2 (Figure 2.2B) suggesting 
that the c-IAP proteins were sensitive to ubiquitination and proteasomal degradation.   
In order to determine if the ubiquitination and degradation of c-IAP1 and c-IAP2 
was due to the E3 ubiquitin ligase activity in their RING domains, site-directed 
mutagenesis was performed to replace critical histidines within their RING domains 
(H588A for c-IAP1 and H574A for c-IAP2).  Interestingly, the expression of c-IAP1 and 
c-IAP2 variants deficient in their E3 ubiquitin ligase activities was greatly enhanced 
relative to their wild type counterparts and was comparable to that of wild type XIAP 
(Figure 2.2C).  While loss of the E3 ubiquitin ligase activity of the RING domains 
resulted in stable forms of c-IAP1 and c-IAP2, modification of the corresponding critical 
histidine in the RING domain of XIAP did not result in a change in the expression level 
of XIAP H467A compared to wild type XIAP.   Collectively, these data indicate that 
when expressed alone in culture, both c-IAP1 and c-IAP2 undergo RING-dependent 
autoubiquitination and degradation.  
 
TRAF2 enhances the expression of c-IAP1 post-translationally 
Since a reduction in endogenous c-IAP1 protein levels was observed that 
corresponded to reduced TRAF2 protein levels, and the c-IAP proteins were observed to 
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undergo autoubiquitination mediated by their E3 ubiquitin ligase activity when expressed 
alone in culture, we sought to determine if overexpression of any TRAF proteins might 
alter IAP protein levels. As shown in Figure 2.3, c-IAP1, c-IAP2, and XIAP were 
expressed with TRAF1 through 6.  Surprisingly, expression of TRAF2 caused a marked 
enhancement in the expression of c-IAP1, whereas no other TRAF proteins significantly 
enhanced the expression of c-IAP proteins (Figures 2.3A and 2.3B).  TRAF1 slightly 
enhanced the expression of c-IAP1, however the possibility that this effect could be due 
to heterodimerization of TRAF1 with TRAF2 remains untested.  While enhanced 
expression of the c-IAP proteins, most notably c-IAP1, was observed in the presence of 
TRAF2, the expression of XIAP was unchanged by all tested TRAF proteins (Figure 
2.3C). 
These data indicated that TRAF2 was capable of stabilizing c-IAP1.  We 
therefore examined whether the enhanced expression of c-IAP1 in the presence of 
TRAF2 was associated with a decrease in c-IAP1 autoubiquitination (Figure 2.4A).  To 
investigate this hypothesis, the RING mutant of c-IAP1 was expressed with TRAF2, 
since the RING mutant of c-IAP1 is stable and does not undergo autoubiquitination.  
Coexpression of TRAF2 and the RING mutant of c-IAP1 (H588A) did not lead to 
additional enhancement of c-IAP1 H588A protein levels (Figure 2.4A).  These data 
suggest that the association of TRAF2 with c-IAP1 might impairs the ability of c-IAP1 to 
undergo autoubiquination.  
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Figure 2.3:  TRAF2 selectively stabilizes c-IAP1.  (A) HEK293 cells were transfected with a 
plasmid encoding HA-c-IAP1 in the presence each of the six TRAFs.  Twenty-four hours 
following transfection, cell lysates were prepared and immunoblot analysis was performed for 
HA-c-IAP1.  (B) HEK293 cells were transfected with a plasmid encoding HA-c-IAP2 in the 
presence each of the six TRAFs.  Twenty-four hours following transfection, cell lysates were 
prepared and immunoblot analysis was performed for HA-c-IAP2.  (C) HEK293 cells were 
transfected with a plasmid encoding HA-XIAP in the presence each of the six TRAFs.  Twenty-
four hours following transfection, cell lysates were prepared and immunoblot analysis was 
performed for HA-XIAP.  Immunoblot analysis was performed to confirm equivalent expression 
of all six TRAF proteins in A-C, and equivalent protein loading was verified in A-C by 
immunoblotting for β-actin.  
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Figure 2.4:  TRAF2 mediated c-IAP1 stabilization occurs post-translationally and does not 
require the RING of TRAF2.  (A) HEK293 cells were transfected with HA-c-IAP1 or HA-c-
IAP1 H588A, the c-IAP1 RING mutant, in the presence of TRAF2.  Twenty-four hours following 
transfection, cells were harvested and immunoblot analysis was performed for HA-c-
IAP1/H588A and TRAF2.  (B) HEK293 cells were transfected with HA-c-IAP1 in the presence 
of TRAF2 or ∆RING TRAF2, a variant of TRAF2 which lacks the RING domain (residues 1-86).  
Twenty-four hours following transfection, cell lysates were prepared and immunoblotted for HA-
c-IAP1 and TRAF2/∆RING TRAF2.  Equivalent protein loading was verified in A and B by 
immunoblotting for β-actin. (C) HEK293 cells were transfected with expression plasmids 
encoding HA-c-IAP1 in the absence or presence of TRAF2, or an empty control plasmid, as 
indicated.  Twenty-four hours following transfection, quantitative analysis by real time reverse 
transcription was performed.  Total RNA was extracted, reverse transcribed, and cDNA was 
analyzed by real-time PCR using a Taqman probe for the BIRC2 gene. The data shown in C are 
the averages ± S.D. for multiple independent samples.  T-test analysis was performed to calculate 
significance, and p-values of less than 0.01 are indicated with an asterisk (*). 
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TRAF2 has previously been reported to participate in the activation of several 
NF-κB signaling pathways (Wang et al., 1998), which in turn leads to the transcriptional 
activation of numerous genes involved in the acute phase of the inflammatory response, 
including BIRC2 (c-IAP1) and BIRC3 (c-IAP2) (Wang et al., 1998).  To determine 
whether TRAF2 might be affecting transcription of BIRC genes, a variant of TRAF2 
lacking the amino-terminal RING domain of TRAF2 (∆RING TRAF2) was utilized.  
This variant of TRAF2 has previously been shown to block NF-κB activation by various 
members of the TNF receptor superfamily, including TNFR2, CD40 and CD30 (Rothe et 
al., 1995b; Duckett et al., 1997).  The ∆RING TRAF2 variant was able to stabilize c-
IAP1 protein levels (Figure 2.4B) indicating that the RING domain of TRAF2 is not 
required for stabilization of c-IAP1.  Furthermore, the increase in c-IAP1 protein levels 
observed in the presence of TRAF2 was not the result of NF-κB activation, since ∆RING 
TRAF2 blocks NF-κB activation (Rothe et al., 1995b). 
To further examine whether TRAF2 was enhancing c-IAP1 post-translationally or 
by transcriptional upregulation, RNA transcript levels of c-IAP1 were examined in the 
absence and presence of TRAF2 by quantitative analysis using real time reverse 
transcription-PCR.  No increase in c-IAP1 transcript levels was observed when TRAF2 
was expressed with c-IAP1 (Figure 2.4C).  Collectively, these results support that 
TRAF2-mediated c-IAP1 stabilization occurs not through NF-κB activation and 
transcriptional upregulation, but through a post-translational interaction between TRAF2 




Stabilized c-IAP1 is cytoprotective 
Since either coexpression of c-IAP1 with TRAF2 or mutation of the RING 
domain within c-IAP1 produced a stabilized c-IAP1, we sought to determine whether 
stabilized c-IAP1 might be capable of conferring a cytoprotective effect.  To activate a 
well-described, caspase-dependent apoptotic program, Bax was ectopically expressed in 
HEK293 cells (Bratton et al., 2002).  Prior studies have shown that XIAP can suppress 
this Bax-induced apoptotic process (Deveraux et al., 1999).  Expression of c-IAP1, 
stabilized by coexpression of TRAF2, induced a significant reduction in caspase 
activation in comparison to Bax expressed alone or c-IAP1 expressed without TRAF2.  
The level of protection by c-IAP1 stabilized by TRAF2 was comparable to the level of 
protection observed for XIAP (Figure 2.5A).  The ubiquitin ligase-deficient variant of c-
IAP1 (H588A) was also capable of robustly protecting cells from undergoing Bax 
induced apoptosis (Figure 2.5B).  Additionally, c-IAP1 stabilized by the ∆RING TRAF2 
variant was capable of protecting against Bax induced cell death to a level comparable to 
c-IAP1 stabilized by TRAF2 (data not shown), suggesting that TRAF2 was not providing 
protection from cell death by activating the NF-κB signaling pathways.  Taken together, 
these data suggest that stabilized c-IAP1 is a potent inhibitor of cell death capable of 





Figure 2.5:  TRAF2 stabilized c-IAP1 and the c-IAP1 RING mutant suppress Bax-mediated 
cell death.  (A) HEK293 cells were transfected with c-IAP1 or XIAP plasmids in the absence or 
presence of TRAF2, along with Bax.  Sixteen hours following transfection, the presence of 
caspase-3 activity was determined by incubation with the fluorogenic substrate, DEVD-AFC.  (B) 
HEK293 cells were transfected with c-IAP1 in the absence or presence of TRAF2, and the c-
IAP1 RING mutant H588A in the presence of Bax. Sixteen hours following transfection, the 
presence of caspase-3 activity was determined by incubation with the fluorogenic substrate, 
DEVD-AFC.  The data shown in A and B are the averages ± S.D. for multiple independent 
samples, and are the result of at least three independent experiments.  T-test analysis was 
performed to calculate significance, p-values of less than 0.01 are indicated with an asterisk (*) 
and p-values of less than 0.05 are indicated with two asterisks (**).  
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Figure 2.6:  c-IAP1 competitively associates with Smac.  HEK293 cells were transfected with 
increasing amounts of the expression plasmid, HA-c-IAP1 H588A (0-8 µg/10 cm2 plate).  
Twenty-four hours following transfection, lysates were precipitated with XIAP or HA antibodies.  
Immunoblot analysis was then performed to evaluate the presence of Smac in the precipitate.  
Immunoblot analysis was also performed on the input lysates to verify the protein levels of HA c-
IAP1, and endogenous XIAP and Smac. Equivalent protein loading was verified by 
immunoblotting for β-actin. 
 
c-IAP1 competitively inhibits the interaction between Smac/DIABLO and XIAP 
Prior reports suggest that c-IAP proteins function to inhibit cell death without 
directly inhibiting the enzymatic activity of caspases (Eckelman and Salvesen, 2006; 
Tenev et al., 2004; Suzuki et al., 2001).  Based on these findings and our observations 
that stabilized c-IAP1 can protect against Bax induced cell death, the binding interaction 
between c-IAP1 and Smac/DIABLO was examined to determine if c-IAP1 was capable 
of protecting cells indirectly, for example by sequestering Smac/DIABLO away from 
endogenous XIAP.  This hypothesis was tested by transfecting increasing amounts of a 
plasmid encoding c-IAP1 H588A, immunoprecipitating either XIAP or c-IAP1 from cell 
lysates, and immunoblotting for Smac/DIABLO in precipitated complexes (Figure 2.6).  
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As the expression level of c-IAP1 increased, the amount of endogenous Smac/DIABLO 
that was precipitated with c-IAP1 also increased.  Interestingly, at the same time, the 
amount of endogenous Smac/DIABLO that was precipitated with endogenous XIAP was 
reduced (Figure 2.6).  These data indicate that stabilized c-IAP1 can competitively inhibit 




In this study, we investigated the mechanisms by which c-IAP proteins are 
regulated, and found that TRAF2 stabilized c-IAP1 (Figure 2.3).  We demonstrated that 
stabilized c-IAP1 was capable of inhibiting cell death to a level comparable to the potent 
cell death inhibitor, XIAP (Figure 2.5).  While XIAP is considered the major mammalian 
cell death inhibitor because it is capable of binding to and inhibiting caspases, c-IAP1 
and c-IAP2 were shown to bind but not inhibit the enzymatic activity of caspases 
(Eckelman and Salvesen, 2006; Tenev et al., 2004).  Therefore, it has been hypothesized 
that c-IAP1 might instead interfere with the binding of the XIAP antagonist, 
Smac/DIABLO, and function to sequester Smac/DIABLO from neutralizing the apoptotic 
inhibition of XIAP (Eckelman and Salvesen, 2006; Tenev et al., 2004).  Using stabilized 
c-IAP1, the anti-apoptotic properties of c-IAP1 were examined.  As demonstrated here, c-
IAP1 can sequester Smac/DIABLO and competitively interfere with Smac/DIABLO 
binding to XIAP, releasing XIAP to inhibit caspases (Figure 2.6).  Therefore, these 
findings provide evidence that stabilized c-IAP1 is capable of protecting against cell 
death, however the mechanism by which stabilized c-IAP1 protects against cell death is 
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distinct from the protective mechanism utilized by XIAP.  Our studies describe a 
mechanism by which c-IAP1 inhibits cell death and clarify how IAP proteins function to 
promote cell survival. 
Although c-IAP1 and c-IAP2 are members of the IAP family because they both 
contain three BIR domains, the structural motif used to define IAP proteins, it is now 
evident that these molecules participate in additional signaling pathways.  The 
observation that c-IAP1 can function as a putative oncogene through synergizing with c-
MYC (Xu et al., 2007) and the presence of c-IAP1 in an amplicon associated with 
squamous cell carcinoma and hepatocellular carcinoma, where c-IAP1 expression 
correlates with resistance to radiotherapy (Imoto et al., 2001; Zender et al., 2006), 
provide important indications of the significant but not yet fully defined cellular functions 
of c-IAP1.  Recently, much interest has been placed on understanding the non-apoptotic 
role of c-IAP proteins in TNF receptor signaling to NF-κB because of their association 
with TRAFs (Vince et al., 2007; Varfolomeev et al., 2007; Petersen et al., 2007; Gaither 
et al., 2007).  c-IAP1 and c-IAP2 play an important role in TNF receptor-mediated 
cellular proliferation through the activation of NF-κB (Vince et al., 2007; Varfolomeev et 
al., 2007; Petersen et al., 2007; Tang et al., 2003; Gaither et al., 2007).  Furthermore, the 
discoveries of compounds that selectively target c-IAP proteins are being thoroughly 
investigated because of their potential therapeutic effects (Vince et al., 2007; 
Varfolomeev et al., 2007; Petersen et al., 2007; Gaither et al., 2007).  
Since it is clear that c-IAP proteins may be an important target for cancer 
therapeutics, it is critical that all cellular roles of c-IAP proteins - both non-apoptotic and 
apoptotic – are thoroughly investigated, because it is evident that c-IAP1 and c-IAP2 are 
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multifunctional proteins that play important roles in cell survival and proliferation, as 
well as other potential signaling cascades.  Given that c-IAP1 and c-IAP2 have the 
potential to regulate signaling to NF-κB through interactions with TRAFs, as well as 
associate with Smac/DIABLO, which can regulate caspase-mediated apoptosis and 
caspase-independent signaling, it is not surprising that numerous forms of cancer may 
utilize c-IAP1 to drive oncogenesis.  While the anti-apoptotic and NF-κB mediated cell 
proliferation roles for c-IAP1 and c-IAP2 are now more defined, it will be imperative to 
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The cellular Inhibitor of Apoptosis factor c-IAP1 has recently emerged as a 
negative regulator of the non-canonical NF-κB signaling cascade.  While synthetic IAP 
inhibitors have been shown to trigger the autoubiquitination and degradation of c-IAP1, 
less is known about the physiological mechanisms by which c-IAP1 stability is regulated.  
Here we describe two distinct cellular processes that lead to the targeted loss of c-IAP1.  
Recruitment of a TRAF2:c-IAP1 complex to the cytoplasmic domain of specific 
members of the TNF receptor superfamily leads to the targeting and degradation of the 
TRAF2:c-IAP1 heteromer through a mechanism requiring the RING domain of TRAF2, 
but not c-IAP1.  In contrast, the induced autoubiquitination of c-IAP1 by IAP antagonists 
causes the selective loss of c-IAP1, but not TRAF2, thereby releasing TRAF2.  Thus, c-
IAP1 can be targeted for degradation by two distinct processes, revealing the critical 




Inhibitor of apoptosis (IAP) proteins are a broadly expressed group of 
intracellular factors that function in a wide range of cellular processes in addition to their 
initially described role in the suppression of programmed cell death (Srinivasula and 
Ashwell, 2008).  A growing body of work is revealing alterations in both expression and 
activity of numerous IAP proteins in neoplastic, lymphoproliferative and metabolic 
disorders, although given the diverse range of functions attributed to these proteins, the 
specific contributions of the IAP proteins to these disorders are still being elucidated 
(Hunter et al., 2007; Mufti et al., 2006; Rigaud et al., 2006). 
IAP proteins contain one to three tandem repeats of an ~70 residue baculovirus 
IAP repeat (BIR) domain (Eckelman et al., 2006).  In addition, several members of the 
IAP family, including the cellular IAP proteins (c-IAP1 & c-IAP2), contain a carboxy-
terminal RING domain that possesses E3 ubiquitin ligase activity (Vaux and Silke, 2005; 
Yang et al., 2000).  Several IAP proteins have been implicated in the regulation of cell 
death through their ability to bind and enzymatically inhibit certain members of the 
caspase family, which are the primary effectors of the apoptotic program.  However, IAP 
proteins differ remarkably in their caspase-inhibiting ability, with X-linked IAP (XIAP) 
being the best described caspase inhibitor, while c-IAP1 and c-IAP2 can bind caspases 
but do not inhibit their enzymatic activity (Eckelman and Salvesen, 2006; Deveraux et 
al., 1998).  Originally identified through their association with the tumor necrosis factor 
receptor 2 (TNFR2), c-IAP1 and c-IAP2 are recruited to tumor necrosis factor (TNF) 
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receptors by tumor necrosis factor receptor-associated factors (TRAFs), primarily TRAF2 
(Rothe et al., 1995). 
CD30, a member of the tumor necrosis factor receptor superfamily, has been the 
subject of much investigation because of its greatly elevated expression in several types 
of leukemia and lymphoma cells, including anaplastic large cell lymphoma (ALCL) and 
Hodgkin’s lymphoma (HL) (Stein et al., 2000; Younes and Carbone, 1999).  Normally, 
CD30 expression is restricted to a small subset of activated B- and T-cells, and has been 
shown to induce downstream signaling events through TRAFs, similarly to other 
members of the TNF receptor family such as TNFR2 and CD40.  In particular, the 
activated CD30 receptor leads to the activation of the nuclear factor κB (NF-κB) 
transcription factor cascade through a mechanism that is largely TRAF-dependent 
(Duckett et al., 1997; Lee et al., 1996; Aizawa et al., 1997; Boucher et al., 1997).  
Induction of NF-κB-responsive genes is critical for immune responses, cell survival and 
proliferation, and the upregulation of CD30 in leukemia and lymphoma cells promotes 
aberrant NF-κB activation driving lymphomagenesis (Horie et al., 2004; Horie et al., 
2002).  Two major NF-κB pathways have been described both of which are activated in 
response to CD30 stimulation (Wright et al., 2007). The canonical pathway involves 
phosphorylation of IκBα, and in the alternative pathway p100/NF-κB2 is proteolytically 
processed to p52 (Hayden and Ghosh, 2008). 
c-IAP1 and c-IAP2 were originally identified as TRAF associated proteins (Rothe 
et al., 1995), and c-IAP1 was identified in amplicons associated with squamous cell 
carcinoma and hepatocellular carcinoma, in which elevated expression correlates with 
resistance to radiotherapy (Imoto et al., 2001; Zender et al., 2006).  More recently, c-
 59 
IAP1 was identified as a putative oncogene, functioning synergistically with c-MYC, in a 
murine hepatocellular carcinoma genetic screen (Zender et al., 2006), and independently 
c-IAP1 was also shown to target the c-MYC regulatory factor, MAD1, for proteasome-
mediated degradation (Xu et al., 2007). 
Previous reports have revealed several elegant mechanisms by which the activity 
of IAP proteins can be regulated.  For instance, a number of mitochondrial proteins have 
been identified that are released into the cytosol during apoptosis, along with cytochrome 
c, which can bind to and antagonize IAP proteins (Du et al., 2000; Suzuki et al., 2001).  
The mammalian prototype of these factors that contain the so-called IAP binding motif 
(IBM) is second mitochondrial-derived activator of caspase (Smac, DIABLO in mice), 
which was originally identified as an XIAP antagonist, but which has been subsequently 
shown to also recognize other IAP proteins, including c-IAP1.  Many of the binding 
properties of Smac can be recapitulated by a conserved tetrapeptide sequence, and small 
molecule IAP antagonists that mimic the action of Smac have been designed to potentiate 
apoptosis in cancer cells (Arnt et al., 2002; Wu et al., 2007).  Additionally, Smac can be 
selectively released from mitochondria in the absence of an apoptotic stimulus, and 
indeed, in healthy cells cytosolic Smac has been described, produced either as an 
alternatively spliced variant whose maturation has been shown to bypass mitochondria, or 
through other less well-defined processes (Deng et al., 2003; Roberts et al., 2001).  These 
findings suggest that the regulation of IAP proteins may be of central importance in the 
homeostatic control of a number of physiological processes in addition to apoptosis. 
Here we examine the functional consequences reflected by the cellular 
interactions between c-IAP1, TRAF2 and Smac.  We describe two apparently 
 60 
independent mechanisms by which c-IAP1 can be targeted for degradation.  Receptor-
mediated cellular activation induces the degradation of a TRAF2:c-IAP1 complex 
through the E3 ubiquitin ligase activity of TRAF2 which is mediated by its RING.  In 
contrast, Smac or a synthetic IAP antagonist triggers the selective degradation of c-IAP1, 
but not TRAF2, through the RING of c-IAP1.  The consequence of c-IAP1 targeting by 
either of these processes is the activation of the non-canonical NF-κB pathway, 
consistent with previously proposed mechanisms for the role of c-IAP1 in this signaling 
cascade. Since NF-κB activation has frequently been associated with the transcriptional 
induction of gene signatures involved in cytoprotection, these findings indicate that the c-
IAP proteins and IBM-containing proteins such as Smac can function in pro-apoptotic 




Materials:  Reagents were obtained from the following sources: Ni-NTA-agarose 
(Invitrogen), DMSO (Sigma Aldrich), Cell culture media (Mediatech), Ficoll-paque 
PLUS (GE Healthcare), and Quik-Change site-directed mutagenesis kit (Stratagene).  
AEG40730 was a kind gift from Aegera Therapeutics.  Antibodies were obtained from 
the following sources: TRAF2 (BD Pharmingen), COX IV (Invitrogen), Smac/DIABLO 
(Calbiochem), GST (Santa Cruz), peroxidase conjugated anti-HA, peroxidase conjugated 
anti-FLAG, β-actin (Sigma Aldrich) and p52/p100 (Upstate).  Peroxidase-conjugated 
anti-mouse, anti-rabbit and anti-rat (GE Healthcare).  Anti-c-IAP1 was kindly provided 
by Dr. John Silke (La Trobe University, Melbourne) (Vince et al., 2007). 
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Plasmids:  pEBB-HA c-IAP1 was subcloned from pEBG c-IAP1 (Duckett et al., 1998).  
Site-directed mutagenesis of c-IAP1 to generate c-IAP1 H588A was performed using the 
Quikchange Mutagenesis Kit (Stratagene).  pEBB His6-Ub was a kind gift of Dr. Ezra 
Burstein (University of Michigan).  Unless otherwise noted, plasmids used for this study 
have been described previously (Duckett and Thompson, 1997; Wilkinson et al., 2004b; 
Wilkinson et al., 2008). 
 
Cell Lines:  HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium, 
Karpas 299 and L428 cells were cultured in RPMI medium, and CHO cells were cultured 
in F-12 nutrient medium.  All media was supplemented with 10% fetal bovine serum and 
2 mM L-glutamine and maintained at 37 ˚C in an atmosphere of 95% air, 5% CO2.  
 
Transfections:  HEK293 cells were transfected with plasmids using a standard calcium 
phosphate transfection protocol.  Both plasmids and siRNA oligonucleotides were 
transfected into Karpas 299 cells using a Bio-Rad Gene Pulser II electroporator set on 
infinite resistance, 300 V and 950 microfarads.  
 
Physiological CD30 Stimulation and Treatment with AEG40730:  Stimulation of 
Karpas 299 cells with CD30L+ CHO cells was performed as previously described 
(Wright et al., 2007).  Briefly, Karpas 299 cells were resuspended in a 1:1 mixture of 
RPMI and F-12 nutrient media at a final concentration of 106 cells/mL.  CHO cells 
(negative control) or CD30L+ CHO cells were seeded 24 hours prior at 0.8 x 106 
cells/well, and 1 mL of Karpas 299 cells were layered on CHO cells in 6-well plates for 2 
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hours.  Karpas 299 cells were then removed from the CHO cells by gentle pipetting and 
collected by centrifugation for 5 min at 200 x g.  Cells were washed with 1 mL PBS, and 
subsequently centrifuged for 5min at 200 x g, and resuspended in RIPA lysis buffer (PBS 
containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 
protease inhibitors. HEK293 or Karpas 299 cells were treated with 0-25 nM AEG40730 
for 24 hours, or treated for 0-48 hours with 25 nM AEG40730, as described in results. 
DMSO was used as a control for all AEG40730 treatments. 
 
Cell Lysate Preparation and Immunoblot Analysis:  Cell lysates were prepared with 
RIPA lysis buffer, supplemented with protease inhibitors, for 30 min on ice to ensure 
complete lysis unless noted otherwise.  Protein quantitation was determined by Bradford 
assay (Bio-Rad). RIPA cell lysates of equal protein concentrations were prepared in LDS 
sample buffer, separated on denaturing NuPAGE 4-12% polyacrylamide gradient gels, 
and transferred to 0.45 µM nitrocellulose membranes (Invitrogen).  Membranes were 
blocked in 5% milk in Tris buffered saline (TBS) with 0.02 - 0.2% Tween 20 (Bio-Rad) 
depending on the antibody requirements, followed by incubation with the indicated 
antibodies in 2.5% milk for 1 hour at room temperature or overnight at 4 ˚C.  After 
washing with TBS containing 0.02-0.2% Tween, membranes were incubated with 
secondary antibodies for 1 hour at room temperature.  Enhanced chemiluminescence (GE 
Healthcare) was used to visualize the blots. 
 
Cellular Fractionation Preparation:  Karpas 299 or L428 cells (106 cells/treatment) 
were prepared as described previously (Wilkinson et al., 2004a), with minor protocol 
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modifications.  Cells were harvested, washed with PBS, resuspended at 3 x 107 cells/mL 
in digitonin extraction buffer (PBS containing 250 mM sucrose, 70 mM KCl, 1 mM 
phenylmethylsulfonyl fluoride, 200 µg digitonin/mL) supplemented with additional 
protease inhibitors.  Following incubation on ice for 5 min, samples were centrifuged for 
5 min at 1,000 x g.  RIPA lysis buffer was used to lyse sample pellets, as described 
above.  Supernatants (cytoplasmic extracts) were collected and centrifuged again at 1,000 
x g for 5 min to remove any residual debris.  Extract protein concentrations were 
normalized using a Bradford assay (Bio-Rad). 
  
RNA Interference:  Cells (107 cells/ transfection) were transfected with 16 µg of short 
interfering RNA oligonucleotides (Xeragon/Qiagen) by electroporation.  Gene-specific 
targeting of Smac was performed using a previously described oligonucleotide 
corresponding to nucleotides 156-176 of the coding sequence of Smac (Wilkinson et al., 
2004b).  As a negative control, a previously described oligonucleotide corresponding to 
nucleotides 322-342 of GFP was utilized (Wilkinson et al., 2004b).  24 hours following 
electroporation, dead cells were removed by centrifugation the cells at 400 x g for 20 min 
on a Ficoll-Pique PLUS density cushion.  Forty-eight hours post-transfection, CD30 was 
stimulated on the transfected cells for 2 hours as described above.  Following CD30 
stimulation, total RNA was isolated from half of the cells and subjected to real time 
reverse transcription-PCR.  The remaining fraction of cells was used for whole cell lysate 
preparation and Western blot analysis. 
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Real Time Reverse Transcription-PCR:  Karpas 299 cells were transfected with 
plasmids or oligonucleotides, stimulated with CD30L for 2 hours as described above and 
then washed with PBS. Total RNA was isolated using the RNeasy minikit (Qiagen) 
according the manufacturer’s instructions.  Reverse transcription with random hexamer 
primers and MultiScribeTM Reverse Transcriptase (Applied Biosystems) was performed 
on 100 ng of total RNA.  The indicated target assays were performed on 1 µL of resulting 
cDNA.  Each target assay was performed in triplicate and normalized to glyceraldehydes 
3-phosphate dehydrogenase. 
 
Ubiquitin Precipitations:  To detect His-Ubiquitin conjugated proteins, cell lysates were 
prepared in 8 M Urea lysis buffer (300 mM NaCl, 0.5% Nonident P-40, 50 mM NaPO4, 
50 mM Tris pH 8.0, and 1 mM phenylmethylsulfonyl fluoride) followed by sonication 
(25 pulses at output control 2.5, 75% duty cycle), normalized for protein content, and 
incubated with Ni-Agarose beads for 2 hours at 4°C.  Agarose beads were recovered by 
centrifugation, washed in 8 M Urea lysis buffer, and precipitated proteins were eluted by 
adding LDS sample buffer (Invitrogen) and heating samples for 10 min at 95°C.  
Recovered proteins were subsequently separated by electrophoresis, and immunoblot 









CD30 signaling activates the non-canonical NF-κB pathway and the degradation of 
both c-IAP1 and TRAF2 
Ligand-mediated activation of many members of the TNF receptor superfamily, 
including CD30, initiates a series of intracellular signal transduction cascades (Baud and 
Karin, 2001).  The non-canonical NF-κB signaling pathway is activated by CD30, and is 
thought to utilize the signaling intermediate, TRAF2, which binds directly to the 
cytoplasmic tail of CD30 (Duckett et al., 1997; Lee et al., 1996; Aizawa et al., 1997; 
Boucher et al., 1997).  In earlier studies, we found that receptor activation rapidly 
induced the degradation of TRAF2 (Duckett and Thompson, 1997; Wright et al., 2007), 
and we proposed a model in which the depletion of TRAF2 serves both to ‘reset’ the 
signaling pathway and to facilitate crosstalk with other classes of receptors that also 
utilize TRAF2.  Since c-IAP1 is a known TRAF2 binding protein that has recently been 
described as a regulator of NF-κB, we sought to determine whether c-IAP1 was also 
depleted following receptor activation, along with TRAF2, or whether the loss of TRAF2 
displaced the c-IAP1 protein.   
To compare the stability of c-IAP1 before and after receptor activation, we 
employed an experimental approach in which CD30+ anaplastic large cell lymphoma 
(ALCL) cells are activated by the ligand for CD30 (CD30L), using an adherent cell line 
in which CD30L has been stably expressed (Wright et al., 2007).  ALCL cells were 
layered onto adherent CD30L-expressing cells, or control cells, and c-IAP1 levels in the 
ALCL cells were subsequently examined between 0 to 5 hours by immunoblotting.  
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Interestingly, activation by CD30 resulted in a rapid loss of c-IAP1 (Figure 3.1A), 
concomitant with the loss of TRAF2, which we described previously using this system 
(Wright et al., 2007).  Importantly, CD30 activation also induced the non-canonical NF-
κB pathway, as monitored by analysis of the processing of the p100 NF-κB subunit to its 
mature, p52 form (Figure 3.1A, upper panel).  In light of recently proposed models in 
which c-IAP1 functions to suppress the levels and activities of factors involved in the 
non-canonical NF-κB pathway, notably NIK and RIP1, through mechanisms thought to 
involve the E3 ubiquitin ligase activity of c-IAP1 (Gaither et al., 2007; Petersen et al., 
2007; Varfolomeev et al., 2007; Vince et al., 2007), these findings suggest a mechanism 
by which CD30 signaling activates the non-canonical pathway by triggering c-IAP 






Figure 3.1: CD30 activation induces the degradation of both c-IAP1 and TRAF2. (A) Karpas 
299 cells were layered onto Chinese hamster ovary (CHO) cells, or CHO cells expressing CD30 
ligand, for the indicated periods of time. Cells were recovered, lysed in RIPA buffer, and 
immunoblotted, for p100/p52, c-IAP1, TRAF2, or β-actin. (B) Site-directed mutagenesis was 
performed to convert the histidine residue 588 to alanine (H588A) located within the RING 
domain of c-IAP1 to generate a mutant c-IAP1 deficient in E3 ubiquitin ligase activity. HEK293 
cells were transfected with plasmids encoding TRAF2, HA c-IAP1 or HA c-IAP1 H588A as 
indicated, together with a control plasmid or a constitutively active form of CD30. Twenty-four 
hours following transfection, cell lysates were prepared and immunoblot analysis was performed 
for HA c-IAP1/H588A and TRAF2.  Equivalent protein loading was verified by immunoblotting 
for β-actin. 
 
Receptor-induced degradation of the TRAF2:c-IAP1 complex does not require the 
E3 ubiquitin ligase activity of c-IAP1   
Previous studies found that receptor-induced degradation of TRAF2 required an 
intact amino terminal RING domain (Duckett and Thompson, 1997), consistent with 
subsequent reports that the TRAF2 RING functions as an E3 ubiquitin ligase (Li et al., 
2002).  Since c-IAP1 also functions as an E3 ubiquitin ligase, mediated by a carboxy-
terminal RING domain, we examined the involvement of the RING in the degradative 
process of c-IAP1, as mediated by receptor activation.  The E3 ubiquitin ligase activity of 
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c-IAP1 was rendered inert by changing a critical histidine residue at position 588 within 
the RING domain to alanine (H588A) (Conze et al., 2005; Du et al., 2000).  Human 
embryonic kidney (HEK) 293 cells were subsequently transfected with plasmids 
encoding either wildtype c-IAP1 or c-IAP1 H588A and TRAF2 in combination with a 
control plasmid or a constitutively signaling form of CD30 (Figure 3.1B).  Coexpression 
of c-IAP1 with TRAF2 results in a stabilized form of c-IAP1 (Figure 3.3A and R.A.C & 
C.S.D. manuscript in preparation), while the E3 ubiquitin ligase deficient c-IAP1 H588A 
can be readily detected, and is not further stabilized by the inclusion of TRAF2 (Figure 
3.3A, lane 3).  Upon coexpression with the constitutively active CD30 and subsequent 
analysis of total detergent-soluble proteins by immunoblotting, cellular TRAF2 levels 
were observed to be markedly reduced relative to cells in which the control vector was 
included (Figure 3.1B compare lanes 2-4 versus lanes 6-8), consistent with previous 
reports (Duckett and Thompson, 1997; Wright et al., 2007).  Similarly, c-IAP1 levels 
were reduced in the presence of CD30 signaling (Figure 3.1B, lane 3 versus lane 7), 
supporting the data with endogenous c-IAP1 described in Figure 3.1A. Interestingly, the 
c-IAP1 H588A RING mutant was also degraded (Figure 3.1B, compare lanes 4 versus 8), 
indicating that the E3 ubiquitin ligase activity of c-IAP1 is not required for the 
degradation of c-IAP1 or TRAF2, as induced by CD30 signaling.  This finding that the 
E3 ubiquitin ligase activity of c-IAP1 is not required for degradation following CD30 




Cytosolic Smac selectively induces autoubiquination and proteasome-mediate 
degradation of c-IAP1, but not TRAF2 
The cellular IAP antagonist Smac has been shown to regulate the levels and 
activity of several IAP proteins following the release of Smac from mitochondria into the 
cytosol (Yang and Du, 2004).  Interestingly, despite its mitochondrial targeting, cytosolic 
Smac was readily detectable in ALCL and HL cells (Figure 3.2).  To determine whether 
the mechanism by which Smac targets c-IAP1 for degradation was related to CD30-
induced degradation of c-IAP1 we used a mature cytosolic version of Smac that bypasses 
the mitochondria (Hunter et al., 2003).  Expression of mature Smac resulted in a decrease 
in unmodified c-IAP1 protein and a ladder-like appearance of higher c-IAP1 moieties 
(Figure 3.3A).  In contrast, the expression of mature Smac had no significant impact on 
TRAF2 expression levels.  These findings suggest that the mechanism by which Smac 
regulates c-IAP1 expression is distinct from the mechanism by which c-IAP1 and TRAF2 
are targeted following CD30 activation since only c-IAP1 protein levels are altered in the 
presence of Smac.  
The laddering pattern of c-IAP1 that was observed in the presence of Smac is 
highly suggestive of polyubiquitination.   To determine if Smac could function to induce 
ubiquitination of c-IAP1, HEK293 cells were transfected with a plasmid encoding 
histidine-tagged ubiquitin and combinations of c-IAP1, TRAF2 and Smac.  Cellular 
lysates were prepared and ubiquitinated proteins were precipitated with agarose beads 
coupled to Nickel (Ni-agarose).  Smac expression induced the accumulation of high 
molecular weight, ubiquitinated c-IAP1 (Figure 3.3B).  Interestingly, the ubiquitination 
pattern of TRAF2 was unaffected by Smac (Figure 3.3B, center panel).  Since Smac 
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could induce the polyubiquitination of c-IAP1, but not TRAF2, these data support a 
model in which Smac functions to specifically target c-IAP1 for degradation.  
 
 
Figure 3.2: Smac is located in cytosolic and mitochondrial fractions. Cytosolic and 
mitochondrial fractions were prepared from (A) HL cells (L428) and (B) ALCL cells (Karpas 
299), and the subcellular distribution of Smac was subsequently analyzed by immunoblotting.  
The quality and integrity of the mitochondrial and cytosolic fractions were confirmed by 
reprobing with an antibody directed against cytochrome oxidase subunit IV (COX IV). 
 
Several known E3 ubiquitin ligases could be postulated to catalyze the Smac-
induced ubiquitination of c-IAP1, but since c-IAP1 itself harbors E3 ubiquitin ligase 
activity, a likely possibility is that Smac might facilitate the autoubiquitination of c-IAP1.  
To test this possibility HEK293 cells were transfected with wildtype c-IAP1 or the cIAP1 
H588A mutant in the absence or presence of Smac.  Unlike the pronounced 
ubiquitination ladder observed for wildtype c-IAP1 in the presence of Smac, its 
expression had no effect on the levels of the E3 ubiquitin ligase deficient c-IAP1 (Figure 
3.3C).  These data support a model in which Smac selectively induces the ubiquitin-
mediated degradation of c-IAP1 through its autoubiquitination, while leaving TRAF2 




Figure 3.3: Cytosolic Smac triggers the autoubiquitination and degradation of c-IAP1, but 
not TRAF2. (A) HEK293 cells were transfected with plasmids encoding TRAF2 and HA c-
IAP1, together with an empty control plasmid or a plasmid encoding mature Smac as indicated. 
Cells were harvested 24 hours following transfection, and lysates were analyzed by 
immunoblotting for Smac, HA c-IAP1, and TRAF2. Immunoblotting for β-actin was used to 
verify equivalent protein loading. (B) HEK293 cells were transfected with combinations of Smac-
FLAG, HA c-IAP1, TRAF2 and His-Ub.  Twenty-four hours following transfection, cell lysates 
were prepared in 8 M Urea buffer and precipitated using Nickel beads.  The presence of HA c-
IAP1, TRAF2, and FLAG Smac in the precipitate was determined by immunoblotting.  (C) 
HEK293 cells were transiently transfected with HA c-IAP1 or the c-IAP1 H588A mutant 
expression plasmid along with plasmids encoding for TRAF2 and mature Smac.  Twenty-four 
hours following transfection, cell lysates were prepared and immunoblot analysis was performed 
for HA c-IAP1 / H588A mutant, Smac, and TRAF2.  Equivalent protein loading was verified by 
immunoblotting for β-actin.  
 
c-IAP1 is an inhibitor of the non-canonical NF-κB pathway, and Smac neutralizes 
this inhibition   
Distinct targeting of c-IAP1 alone was observed in the presence of Smac, whereas 
CD30 activation resulted in the degradation of both c-IAP1 and TRAF2.  Since the loss 
of c-IAP1 has been associated with the activation of the non-canonical NF-κB pathway, 
we evaluated the effect of Smac on non-canonical NF-κB activation, by examining the 
processing of the p100 protein to its transcriptionally active p52 form.  Expression of 
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TRAF2 resulted in a significant increase in p100 processing to p52, confirming previous 
studies in which TRAF2 has been implicated in the non-canonical NF-κB pathway 
(Figure 3.4, lane 2) (Wright et al., 2007).  However, coexpression of c-IAP1 with TRAF2 
inhibited the ability of TRAF2 to induce p100 processing (Figure 3.4, lane 3), consistent 
with reports that c-IAP1 functions to suppress the non-canonical pathway by targeting 
NIK for degradation.  Interestingly, expression of mature Smac alone induced p100 
processing (Figure 3.4, compare lanes 2 & 6), and Smac counteracted the inhibitory 
effect of c-IAP1 on p100 processing (Figure 3.4, lane 5).  In the presence of Smac, the 
high molecular weight ladder of polyubiquitinated c-IAP1 was again observed, while 
TRAF2 appeared unaffected.  Therefore, Smac was found to activate the non-canonical 
NF-κB signaling pathway, and this activation occurred concomitantly with induced 






Figure 3.4:  c-IAP1 is an inhibitor of the non-canonical NF-κB pathway, and Smac 
neutralizes c-IAP1 mediated NF-κB inhibition.  HEK293 cells were transfected with mature 
Smac-FLAG, HA c-IAP1 and TRAF2.  Twenty-four hours following transfection, cell lysates 
were prepared and immunoblot analysis was performed for p100/p52, HA c-IAP1, TRAF2, and 
Smac-FLAG.  Equivalent protein loading was confirmed by immunoblotting for β-actin. 
 
 A synthetic IAP antagonist selectively targets c-IAP1 for autoubiquitination 
The data presented in Figures 3.3 and 3.4 indicate that Smac induces a selective 
autoubiquitination of c-IAP1, while leaving TRAF2 unaffected, and that this process 
leads to the activation of the non-canonical NF-κB pathway by inducing the processing 
of the p100 NF-κB subunit.  Since a number of synthetic, cell-permeable IAP antagonists 
have been developed based on the Smac:IAP interface, we examined the possibility that 
an IAP antagonist, AEG40730, would function similarly to mature Smac, by activating 
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the autoubiquitination of c-IAP1, releasing TRAF2, and triggering p100 processing.  
Interestingly, AEG40730 was capable of degrading ectopically expressed c-IAP1 in a 
similar fashion as mature Smac, as increasing concentrations of AEG40730 resulted in 
decreasing levels of c-IAP1 (Figure 3.5A).  Importantly, no differences in the levels of 
TRAF2 were observed.   
 
Figure 3.5:  The IAP antagonist AEG40730 induces the degradation of c-IAP1, but not 
TRAF2. (A) HEK293 cells were transfected with HA c-IAP1 and TRAF2.  Twenty-four hours 
following transfection, cells were treatment with 0, 1, 5, 10 or 25 nM AEG40730 or DMSO.  
Twenty-four hours following treatment with AEG40730, cell lysates were prepared and 
immunoblot analysis was performed for HA c-IAP1 and TRAF2.  Equivalent protein loading was 
confirmed by immunoblotting for β-actin.  As a control, c-IAP1 and TRAF2 were also transfected 
with mature Smac-FLAG. (B) HEK293 cells were transfected with HA c-IAP1 H588A.  Twenty-
four hours following transfection, cells were treatment with 0, 1, 5, 10, or 25 nM AEG40730 or 
DMSO.  Twenty-four hours following treatment with AEG40730, cell lysates were prepared and 
immunoblotted for HA c-IAP1 H588A.  As a control, c-IAP1 H588A was transfected with mature 
Smac-FLAG.  Equivalent protein loading was verified by immunoblotting for β-actin. 
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Given the apparent similarities between the effects of mature Smac and the 
synthetic IAP antagonist, we sought to test whether AEG40730 could induce c-IAP1 
autoubiquitination by analysis of the c-IAP1 E3 ubiquitin ligase mutant H588A in the 
presence of increasing doses of AEG40730.  Similar to the results observed for c-IAP1 
H588A in the presence of mature Smac, the RING mutant of c-IAP1 was insensitive to 
AEG40730 treatment at any tested dosage (Figure 3.5B).  These findings strongly support 
the notion that AEG40730 functions analogously to mature Smac, in the ability to 
stimulate autoubiquitination of c-IAP1. 
 
AEG40730 triggers processing of p100 NF-κB to its p52 form  
Since the IAP antagonist, AEG40730, appeared to trigger c-IAP1 
autoubiquitination in a similar fashion to mature Smac, we next investigated the ability of 
the IAP antagonist to activate the non-canonical NF-κB pathway through c-IAP1 
degradation.  To determine whether AEG40730 was capable of activating the alternative 
NF-κB pathway, we examined p100 processing to p52.  HEK293 (Figure 3.6A) and 
Karpas 299 (Figure 3.6B) cells were treated for twenty-four hours with increasing doses 
of AEG40730.  As before, treatment with AEG40730 induced the loss of endogenous c-
IAP1, whereas endogenous TRAF2 levels were unaffected (Figure 3.6).  Importantly, 
treatment with AEG40740 also resulted in increased processing of p100 to p52, already 
evident by six hours (Figure 3.6C).  Therefore, AEG40730 was capable of selectively 
targeting the degradation of c-IAP1, but not TRAF2, and a concomitant processing of 




Figure 3.6:  Rapid degradation of c-IAP1, but not TRAF2, precedes activation of the non-
canonical NF-κB pathway.   The IAP antagonist AEG40730 triggers processing of p100 to 
p52.  (A) HEK293 cells or (B) Karpas 299 cells were treated with a vehicle control (DMSO) or 0, 
1, 5, 10, 25 nM AEG40730 and incubated for 24 hours. (C) Karpas 299 cells were treated for 0 to 
48 hours with 25 nM AEG40730 or DMSO.  Following treatment with AEG40730, cell lysates 
were prepared and immunoblot analysis was performed for c-IAP1, TRAF2, and p52/p100.  
Equivalent protein loading was confirmed by immunoblotting for β-actin. 
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Both Smac and the IAP antagonist AEG40730 potentiate transcription of 
endogenous NF-κB-dependent genes 
The finding that both Smac and the synthetic IAP antagonist can induce the 
processing of p100 suggested that these agents might also modulate NF-κB-dependent 
transcription, as induced by a defined signal from a TNF receptor superfamily member 
such as CD30.  To test this possibility, Karpas 299 cells were transfected with a plasmid 
encoding mature Smac or with an empty control plasmid, and subsequently stimulated 
with control CHO or CD30L+ CHO cells.  Following stimulation, RNA was isolated and 
quantitative real time-PCR (qRT-PCR) analysis was performed on a panel of previously 
described NF-κB-responsive genes.  Interestingly, the induction of NF-κB-dependent 
genes by CD30 was augmented in cells expressing mature Smac (Figure 3.7A).  
Similarly, pretreatment of Karpas 299 cells with AEG40730 prior to CD30 activation 
resulted in an almost identical augmentation of κB-dependent transcription (Figure 3.7B) 
to that observed following ectopic expression of mature Smac. Therefore, both Smac and 
the IAP antagonist, AEG40730, were found to function indistinguishably in their ability 
to potentiate κB-dependent transcription, in response to CD30 activation.   
While the findings shown in Figures 3.7A and 3.7B demonstrate a potentiation of 
NF-κB-dependent transcription in response to the IAP antagonists or overexpression of 
mature Smac, it remained unclear whether endogenous Smac could play a role in NF-κB 
activation.  To address this issue, endogenous Smac expression was experimentally 
suppressed and expression of defined NF-κB target genes was subsequently analyzed by 
qRT-PCR in response to CD30 activation (data not shown).  Interestingly, Karpas 299 
cells with reduced Smac levels demonstrated a significant decrease in NF-κB-responsive 
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genes following CD30 activation, as compared to cells transfected with control 
oligonucleotides and stimulated in parallel through CD30 (Figure 3.7C).   Altogether, 
these data indicate that Smac plays a role in the expression of NF-κB target genes, 







Figure 3.7:  Smac is a modulator of CD30-mediated signaling and activates transcription of 
endogenous NF-κB-dependent genes.  (A) Karpas 299 cells were electroporated with an 
expression plasmid encoding mature Smac-FLAG, or an empty control plasmid, as indicated.  
Twenty-four hours following transfection, cells were layered onto CD30L+ CHO cells or control 
CHO cells for 2 hours.  Total RNA was extracted and reverse transcribed, cDNA was analyzed by 
quantitative real time PCR (qRT-PCR) using Taqman probes for the indicated NF-κB-dependent 
genes. (B) Karpas 299 cells were treated with 25 nM AEG40730 or DMSO.  Twenty-four hours 
following treatment, cells were layered onto CD30L+ CHO cells or control CHO cells, as 
indicated, for 2 hours.  Total RNA was extracted and reverse transcribed, and cDNA was 
analyzed by quantitative real time PCR (qRT-PCR) using Taqman probes for the indicated NF-
κB-dependent genes. (C) Karpas 299 cells were electroporated with double-stranded siRNA 
oligonucleotides targeting Smac or an irrelevant sequence, as indicated.  Forty-eight hours 
following transfection, cells were layered onto CD30L+ CHO cells or control CHO cells, as 
indicated, for 2 hours.  Total RNA was extracted and reverse transcribed, cDNA was analyzed by 
qRT-PCR using Taqman probes for the indicated NF-κB-responsive genes.   The data shown in 
A, B, and C are the averages S.D. for multiple independent samples.  T-test analysis was 
performed to calculate significance, p-values of less than 0.01 are indicated with an asterisk (*), 
p-values of less than 0.05 are indicated with two asterisks (**), and p-values of less than 0.10 are 




In this study, we examined the cellular regulatory mechanisms for c-IAP1, which 
has recently been shown to function as an NF-κB inhibitory factor.  We found that c-
IAP1 can be regulated by two distinct mechanisms (Figure 3.8).  During CD30 signaling 
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c-IAP1 is targeted for degradation through its association with TRAF2 (Figure 3.1).  On 
the other hand, cytosolic Smac selectively induces the autoubiquitination and 
proteasomal degradation of c-IAP1, while TRAF2 is unaffected by Smac (Figure 3.3 and 
3.4).  These constitute two endogenous cellular mechanism by which c-IAP1 is 
controlled.  Interestingly, a number of earlier reports describe the autoubiquitination and 
degradation of c-IAP proteins after treatment with IAP antagonists (Varfolomeev et al., 
2007; Vince et al., 2007; Yang and Du, 2004).  Our studies indicate that endogenous 
Smac plays a similar role and places this factor in the regulation of NF-kB signaling 
through its effects on c-IAP1.  In addition, our studies provide functional evidence in 
support of the original biochemical screen where c-IAP proteins were found to associate 
with TNFR2 (Rothe et al., 1995). 
The enhanced expression of CD30 in several forms of leukemia and lymphoma 
suggest that CD30 signaling is critical to pathogenesis of these tumors (Horie et al., 2004; 
Horie et al., 2002).  Previous studies have described CD30 as an activator of NF-κB 
signaling and showed that CD30 induces the degradation of TRAF2 (Duckett and 
Thompson, 1997; Wright et al., 2007).  However, the significance of TRAF2 depletion on 
NF-κB activation remained unclear.  Here, we show that CD30 activation not only results 
in the degradation of TRAF2, but also c-IAP1 (Figure 3.1).  Interestingly, the degradation 
of TRAF2 was previously shown to require the RING of TRAF2, whereas the findings 
shown in Figure 3.1B indicate that the E3 ubiquitin ligase activity of the RING in c-IAP1 
is not required for CD30-mediated degradation.  Although exact downstream targets of c-
IAP1 remain unclear, c-IAP1 has been reported to function as an E3 ubiquitin ligase for 
NIK, RIP, and NEMO, and to function as an inhibitor of NF-κB activation (Gaither et al., 
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2007; Petersen et al., 2007; Tang et al., 2003; Varfolomeev et al., 2007; Vince et al., 
2007).  In this context, receptor mediated degradation of c-IAP1 is expected to facilitate 
NF-κB activation.  Our data also provide support for the rationale of targeting c-IAP 
proteins to promote cell death through the activation of an autocrine TNF dependent 
pathway.  Since several immunotherapeutic approaches are being tested for CD30+ 
malignancies, the targeting of IAP proteins in combination with CD30 might be 
especially effective. 
 
Figure 3.8:  Model of the two distinct mechanisms by which the NF-κB regulatory factor c-
IAP1 can be regulated.  Smac and the IAP antagonist induce the selective autoubiquitination 
and degradation of c-IAP1.  In the presence of mature Smac, c-IAP1 but not TRAF2 is degraded.  
Smac promotes processing of p100 to p52 and augments non-canonical NF-κB signaling.  CD30 
activation promotes the degradation of c-IAP1 and TRAF2.  Degradation of c-IAP1 and TRAF2 
requires the RING in TRAF2 but does not require the E3 ubiquitin ligase activity of c-IAP1.  
CD30 signaling results in induction of NF-κB signaling through processing of p100 to the active 
p52 subunit. 
 
The classical role described for IAP proteins was to protect against cell death.  
Although XIAP has been shown to bind to and inhibit caspases, the c-IAP proteins do not 
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inhibit caspase activity.  Similarly, prior work supported Smac as a c-IAP protein 
antagonist, but simple overexpression of Smac does not induce cell death.  These findings 
suggest a non-apoptotic role for the c-IAP1:Smac interaction.  Indeed, earlier reports 
have described a cytosolic localization of Smac in non-apoptotic cells.  Notably, Deng 
and coworkers (Deng et al., 2003) reported the selective release of Smac from the 
mitochondria in colon carcinoma cells following TNF treatment, and others reported the 
existence of an exclusively cytoplasmic variant of Smac, which is thought to be generated 
by alternative splicing of the Smac mRNA transcript (Roberts et al., 2001).  Consistent 
with these reports, we observed the presence of Smac in the cytosol of healthy ALCL and 
HL cells (Figure 3.2), and examined the regulation of c-IAP1 by mature Smac or an IAP 
antagonist.  We found that c-IAP1 underwent autoubiquitination in the presence of 
mature Smac or the IAP antagonist (Figures 3.3, 3.5 and 3.6), supporting prior studies.  
Interestingly, Smac not only induced autoubiquitination of c-IAP1, but also activated the 
non-canonical NF-κB pathway (Figures 3.4, 3.6 and 3.7), as demonstrated by the ability 
of mature Smac to promote processing of p100 to p52 (Figures 3.4, 3.6 and 3.7).  
A provocative earlier study revealed the ability of Smac to be recruited into the 
lymphotoxin-β receptor-signaling complex (Kuai et al., 2003).  Since we found that Smac 
caused increased p100 processing and existed in the cytosol of healthy cells, we 
examined whether Smac would affect CD30-mediated activation of NF-κB.  Indeed, 
ectopic expression of Smac was found to potentiate transcription of endogenous NF-κB -
responsive genes (Figures 3.7A and 3.7B).  Suppression of Smac also resulted in a 
reduction of NF-κB induction (Figure 3.7C).  Therefore, by targeting c-IAP proteins for 
degradation, Smac can function as a highly versatile molecule with the ability to regulate 
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not only caspase-mediated apoptosis, but also caspase-independent signaling pathways 
including, but not restricted to, NF-κB activation.   In this context, Smac might work 
differently to promote cell survival through NF-κB target genes.  It will be of great 
importance to fully understand the intracellular cues that serve to trigger the abilities of 
Smac and potentially other IBM-containing proteins to function physiologically to 
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The development and survival of complex multicellular organisms requires tight 
regulation of numerous intracellular signaling processes to balance the rates of cell death 
and cell growth (Jacobson et al., 1997; Kerr et al., 1972; Meier et al., 2000).  Apoptosis 
or programmed cell death is a critical cellular mechanism to remove unnecessary or 
damaged cells in an organized manner, and programmed cell death is a highly regulated 
process that can be inhibited at several stages by various regulatory factors, including 
BCL-2 and IAP proteins (Salvesen and Duckett, 2002).  Evasion of apoptosis is 
considered a hallmark of cancer, and upregulation of IAPs has been suggested to 
contribute to cancer cell survival through apoptotic inhibition (Hanahan and Weinberg, 
2000).  While IAP proteins share a conserved BIR domain that determines placement in 
the IAP family, it has become increasingly clear that the inhibitory mechanisms utilized 
by various IAP proteins are remarkably different, and that many IAP proteins, including 
c-IAP1, are critical regulators of additional intracellular signaling pathways (Eckelman 
and Salvesen, 2006; Eckelman et al., 2006; Srinivasula and Ashwell, 2008).  The findings 
presented in this dissertation illustrate that c-IAP1 can function as an inhibitor of cell 
death through an indirect mechanism.  Furthermore, this dissertation delineates how c-
IAP1 plays a critical role in the regulation of NF-κB-mediated transcriptional activation 
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 through TNF receptor signaling.  Lastly, this dissertation illustrates how c-IAP1 protein 
levels are regulated by ubiquitination and proteasome-mediated degradation, and the 
consequences of its interaction with distinct factors, namely TRAF2 and Smac/DIABLO. 
 
Cytoprotective Mechanism of c-IAP1  
 
Previous studies have carefully investigated the anti-apoptotic properties of XIAP, 
the ubiquitously expressed prototypical mammalian IAP protein.  Based on biochemical, 
structural and in vivo data, XIAP has been determined to be a potent caspase inhibitor.  
XIAP can bind directly to and inhibit the enzymatic activity of caspase-3, -7, and -9 
(Eckelman et al., 2006).  While XIAP is a potent inhibitor of cell death, the cellular IAP 
proteins have been considered much weaker inhibitory molecules.  While c-IAP proteins 
were found to directly bind caspase-7 and -9, these IAP proteins were incapable of 
inhibiting the enzymatic activities of all tested caspases (Eckelman and Salvesen, 2006).  
Moreover, historically, it has been difficult to characterize the genuine inhibitory 
properties of the c-IAP proteins in biochemical studies since c-IAP proteins are often 
difficult to observe by Western blot.  The carboxy-terminal RING domain present in both 
c-IAP proteins has intrinsic E3 ubiquitin ligase activity that can cause ubiquitination and 
degradation of target proteins (Joazeiro and Weissman, 2000; Dohi et al., 2004; Conze et 
al., 2005; Silke et al., 2005).  Studies in Chapter 2 show that both c-IAP1 and c-IAP2 
undergo autoubiquitination and proteasome-mediated degradation.  Treatment of cells 
with a proteasome inhibitor resulted in a marked increase in c-IAP1 and c-IAP2 protein 
levels.  Additionally, in the same study, mutation of a critical histidine residue in the 
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 RING domains of c-IAP1 and c-IAP2, which has been shown to be important for E3 
ubiquitin ligase activity, resulted in stable forms of c-IAP1 and c-IAP2.  Therefore, the 
study presented in Chapter 2 provided novel evidence that c-IAP proteins are highly 
regulated by autoubiquitination, clarifying why c-IAP proteins are often difficult to detect 
by Western blot. 
Given that a stable form of c-IAP1 was observed in a mutant of c-IAP1 deficient 
in E3 ubiquitin ligase activity, the anti-apoptotic properties of c-IAP1 were investigated.  
Interestingly, the RING mutant of c-IAP1 was found to inhibit cell death to a level 
comparable to XIAP.  Although c-IAP1 cannot inhibit the enzymatic activities of 
caspases, c-IAP1 sequestered Smac/DIABLO, preventing Smac/DIABLO from inhibiting 
XIAP.  Thus, when c-IAP1 sequesters and prevents Smac/DIABLO from antagonizing 
XIAP, this allows XIAP to prevent caspase activity and inhibit execution of cell death.  
Therefore, the studies presented in Chapter 2 of this dissertation suggest that c-IAP1 can 
function as a cell death inhibitor by a mechanism distinct from the mechanism utilized by 
XIAP.  c-IAP1-mediated protection from cell death seems to also rely on the presence of 
XIAP, or other IAP proteins, which can effectively suppress caspases while c-IAP1 
neutralizes Smac/DIABLO or other IAP antagonists.  Figure 4.1 illustrates the distinct 
mechanisms utilized by XIAP and c-IAP1 to inhibit cell death. 
Interestingly, while it was observed that c-IAP1 underwent RING-mediated 
autoubiquitination and degradation, the consequences of the interaction between c-IAP1 
and TRAF2, a previously identified c-IAP1 binding partner, on cell death were largely 
unknown.  Chapter 2 illustrates that c-IAP1 is highly stabilized by TRAF2, the most well 
described TRAF protein that can function as an adaptor molecule for several TNF 
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 receptors, including TNFR2, CD30 and CD40 (Duckett et al., 1997; Chaudhuri et al., 
1997; Rothe et al., 1995b).  Association of TRAF2 with c-IAP1 resulted in stabilization 
of c-IAP1, and TRAF2-deficient MEFs or suppression of TRAF2 by RNA interference 
resulted in a decrease in endogenous c-IAP1 levels.  Interestingly, the RING mutant of c-
IAP1 could not be further stabilized by association with TRAF2, suggesting that 
association of TRAF2 inhibits the autoubiquitination properties of c-IAP1. 
 
 
Figure 4.1: The mechanisms of cell death inhibition by XIAP and c-IAP1. Inhibitor of 
apoptosis (IAP) proteins can inhibit cell death by several mechanisms.  XIAP can bind and inhibit 
the enzymatic activities of caspases, the central executioners of cell death.  Therefore, XIAP is 
considered a potent and direct cell death inhibitor.  c-IAP1 and c-IAP2 can bind to caspases, but 
do not inhibit the enzymatic activities of caspases.  However, c-IAP1 can sequester and inhibit 
Smac/DIABLO, the IAP antagonist released from the mitochondria, from binding to XIAP.  




 While the E3 ubiquitin ligase activity of c-IAP1 seemed to catalyze c-IAP1 
autoubiquitination, it was unclear whether the RING domain within TRAF2 caused 
modification of c-IAP1 or was required for stabilization of c-IAP1 by TRAF2.  The 
studies presented in Chapter 2 suggest that the RING in TRAF2 is not required for c-
IAP1 stabilization by TRAF2.  However, the RING of TRAF2 seemed to promote a 
modified form of c-IAP1, which was not observed in the presence of TRAF2 lacking its 
RING domain.  Besides the native form of c-IAP1, a slightly higher molecular weight 
species of c-IAP1 was observed by Western blot upon coexpression of TRAF2 that may 
represent a monoubiquitinated version of c-IAP1.  Future investigation of this higher 
molecular weight species of c-IAP1 upon coexpression of TRAF2 may reveal a novel 
modification of c-IAP1, which could also affect the anti-apoptotic or non-apoptotic 
signaling properties of c-IAP1. 
Given that TRAF2 stabilized and prevented autoubiquitination of c-IAP1, the 
inhibitory properties of TRAF2-stabilized c-IAP1 on apoptosis were investigated.  
TRAF2-stabilized c-IAP1 effectively inhibited cell death to a level comparable to XIAP, 
and TRAF2 was not found to be responsible for any of the cytoprotective effects 
observed since TRAF2 alone did not protect against cell death.  Therefore, although c-
IAP1 does not directly inhibit the enzymatic activities of caspases, these findings suggest 
that c-IAP1 can function as a cytoprotective molecule when associated with TRAF2. 
It remains to be investigated whether the mechanism of cell death inhibition by 
the c-IAP1 RING mutant and TRAF2-stabilized c-IAP1 are the same.  Since c-IAP1 
stabilized by TRAF2 is still sensitive to autoubiquitination because the E3 ubiquitin 
ligase activity is intact, the ability of TRAF2 stabilized c-IAP1 to inhibit Smac/DIABLO 
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 might be hypothesized to be more transient because Smac/DIABLO can still promote 
TRAF2-stabilized c-IAP1 autoubiquitination, whereas Smac/DIABLO cannot cause 
autoubiquitination of the c-IAP1 RING mutant, as described in Chapter 3.  Although 
TRAF2-stabilized c-IAP1 can undergo autoubiquitination triggered by an association 
with Smac/DIABLO, an intact RING in c-IAP1 might function to promote ubiquitination 
and degradation of Smac/DIABLO, leading to the simultaneous degradation of 
Smac/DIABLO and c-IAP1. 
Furthermore, while the inhibitory properties of c-IAP2 were beyond the scope of 
this dissertation, it remains to be determined if the mechanism by which c-IAP2 can 
protect against cell death is similar to the mechanism described here for c-IAP1.  Since c-
IAP1 and c-IAP2 associate with the same signaling molecules, including TRAF2 and 
Smac/DIABLO, and the c-IAP proteins have highly homologous protein sequences, a 
plausible hypothesis is that c-IAP2 might inhibit cell death through a mechanism similar 
to c-IAP1.  However, investigating the anti-inhibitory properties of c-IAP2 is highly 
challenging, since c-IAP2 has not only been shown to be a target of autoubiquitination, 
but has also been shown to be a target of c-IAP1-mediated ubiquitination and degradation 
(Conze et al., 2005).  Recent data from our laboratory have suggested that c-IAP2-
deficient MEFs have increased sensitivity to several apoptotic stimuli, supporting the idea 
that c-IAP2 has anti-apoptotic properties, although the mechanism utilized by c-IAP2 to 





 Non-Apoptotic Function of c-IAP1 in TNF Signaling 
 
While several IAP proteins have anti-apoptotic properties, it is now well 
established that IAP proteins have multiple cellular functions beyond apoptotic 
inhibition.  As members of the IAP family, c-IAP1 and c-IAP2 were originally 
hypothesized to function primarily in cell death, and the findings in this dissertation 
support that c-IAP1 can function as a cell death inhibitor.  However, involvement of c-
IAP1 and c-IAP2 in TNF signaling is a property unique to the c-IAP proteins.  Although 
the discovery that c-IAP proteins associated with TNFR2 was made in 1995, and it was 
subsequently found that TRAF1 and TRAF2 bridge this association, it remained unclear 
what roles the c-IAP proteins might play in TNF-mediated signaling until recently (Rothe 
et al., 1995a). 
Previous studies from our laboratory and other research groups have shown that 
TRAF2 is an important component of signaling to NF-κB from several TNF receptor 
superfamily members, including CD30, which is upregulated in various forms of 
lymphoma and leukemia (Duckett et al., 1997; Duckett and Thompson, 1997; Boucher et 
al., 1997; Aizawa et al., 1997; Lee et al., 1996; Wright et al., 2007).  Upon CD30 
activation, it was found that TRAF2 was targeted for degradation, which corresponded to 
activation of both the canonical and the alternative NF-κB pathways (Wright et al., 
2007).  Degradation of TRAF2 following CD30 activation was found to be dependent 
upon the presence of the RING domain of TRAF2 (Duckett et al., 1997; Duckett and 
Thompson, 1997).  Based on these findings, and results obtained from TRAF2-deficient 
B cells, TRAF2 is considered to be a critical component of NF-κB signaling that 
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 functions to promote phosphorylation and degradation of IκBα in the canonical 
pathway and stabilization of NIK to promote p100 processing to the active p52 form in 
the alternative pathway (Grech et al., 2004). 
Therefore, given that c-IAP1 and TRAF2 are established binding partners and 
TRAF2 stabilizes c-IAP1, the involvement of c-IAP1 in CD30 mediated NF-κB 
activation was hypothesized.  In Chapter 3, the cellular regulatory mechanisms for c-
IAP1 following CD30 activation were investigated, as well as the downstream effects on 
NF-κB activation.  Indeed, the data presented in Chapter 3 suggest that c-IAP1 regulation 
is critical for NF-κB signaling following CD30 stimulation, since degradation of c-IAP1 
resulted in p100 processing and activation of the non-canonical NF-κB signaling 
pathway.  Specifically, the results in Chapter 3 suggest that like TRAF2, c-IAP1 is 
targeted for ubiquitination and degradation following CD30 activation.  However, unlike 
TRAF2, it was found that the RING of c-IAP1 is not required for degradation of c-IAP1 
following CD30 activation.   
While the findings suggest that the RING of TRAF2 is required for TRAF2 
degradation and the RING of c-IAP1 is not required for c-IAP1 degradation, it will be 
interesting to determine whether the RING of TRAF2 is also required for c-IAP1 
degradation following CD30 stimulation.  Degradation of c-IAP1, as with TRAF2, may 
require the RING domain within TRAF2 in order for docking of the protein(s) that 
catalyzes degradation of c-IAP1 and TRAF2.  Alternatively, the RING of TRAF2 may be 
necessary to promote modifications, including ubiquitination, of c-IAP1 and TRAF2 
necessary for degradation. 
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 The findings presented in Chapter 3 support the model that c-IAP1 functions as 
a negative regulator of NF-κB by inducing the constitutive degradation of one of several 
key NF-κB signaling molecules, including NIK, RIP1, or NEMO (Tang et al., 2003; 
Varfolomeev et al., 2007; Vince et al., 2007).  Several of these signaling molecules have 
been shown to trigger the non-canonical NF-κB pathway by inducing the proteolytic 
cleavage and maturation of p100 to the active p52 form (Senftleben et al., 2001; Xiao et 
al., 2001).  Therefore, if c-IAP1 is targeted for degradation following CD30 activation, 
this allows for the accumulation of the key NF-κB regulatory factors that are normally 
constitutively targeted for degradation by c-IAP1.  Figure 4.2 provides a schematic of the 
current model for the involvement of c-IAP1 in CD30-mediated NF-κB activation. 
 
Figure 4.2: Role of c-IAP1 in the regulation of NF-κB signaling.  Stimulation of TNF 
receptors, including CD30 and TNFR2, promotes activation of the canonical and alternative NF-
κB pathways.  Following TNF receptor activation, NEMO is activated through c-IAP1-mediated 
ubiquitination.  Degradation of TRAF2 and c-IAP1 also results in accumulation of NIK, and other 
NF-κB regulatory factors, which promote activation of the NF-κB signaling pathways. 
*=phosphorylation. 
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 Furthermore, it is clear from the results presented in Chapter 3 that there are two 
distinct pathways by which c-IAP1 can be targeted for degradation – Smac/DIABLO and 
CD30-mediated degradation.  Smac/DIABLO mediated degradation of c-IAP1 is 
dependent upon the presence of the E3 ubiquitin ligase activity of the RING domain in c-
IAP1.  However, the degradation of c-IAP1 following CD30 activation does not require 
an intact RING domain of c-IAP1.  Although the degradation of c-IAP1 by 
Smac/DIABLO was distinct from CD30-mediated degradation and did not result in the 
additional degradation of TRAF2, the surprising finding was that Smac/DIABLO-
mediated c-IAP1 degradation was also capable of promoting NF-κB activation.  
Smac/DIABLO and AEG40730, an IAP antagonist designed around the 
IAP:Smac/DIABLO interface, were capable of inducing p100 processing to p52, and 
transcriptional activation of NF-κB targets.  These findings support a model in which the 
effects of Smac/DIABLO are more complex that promoting cell death by targeting IAP 
proteins for degradation.  Therefore, future evaluation of the impact of Smac/DIABLO or 
IAP antagonists on intracellular signaling will be highly beneficial for our understanding 
of how the cell integrates multiple signaling events. 
Currently, while it is known that Smac/DIABLO is capable of targeting c-IAP1 
for degradation and that this regulatory mechanism is dependent upon the presence of the 
RING within c-IAP1, there are several candidate molecules that facilitate c-IAP1 and 
TRAF2 degradation after CD30 stimulation.  One potential molecule we are currently 
investigating is RIP1, a serine/threonine kinase, which has been shown to associate with 
both TRAF2 and c-IAP1.  At the present time, preliminary data suggest that RIP1 is a 
good candidate, since overexpression of RIP promotes c-IAP1 and TRAF2 degradation in 
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 a manner consistent with CD30 activation, such that the RING of c-IAP1 is not 
required for RIP-mediated degradation, while the RING of TRAF2 is required.   
Collectively, the findings illustrated in Chapter 3 focus on the regulation of c-
IAP1 by Smac/DIABLO and CD30-mediated signaling.  However, it will also be 
interesting to determine whether the same regulation of c-IAP1 occurs by other IAP 
antagonists or through activation of other TNF receptors, such as CD40 and TNFR2.  A 
recent publication by Varfolomeev et al. presented a similar finding for the TWEAK 
receptor, another TNF receptor superfamily member, where c-IAP1 is targeted for 
degradation, and activation of NF-κB occurs simultaneously.  Therefore, it is tempting to 
speculate that the same mechanism of c-IAP1-mediated NF-κB regulation occurs 
following activation of multiple TRAF-domain containing TNF receptors.   
 
c-IAP1 & Cancer 
 
Currently, there is a significant amount of data suggesting that IAP proteins have altered 
expression and/or activity in neoplastic and lymphoproliferative diseases.  Table 4.1 
provides a list of several forms of cancer that have been shown to exhibit alterations in 
IAP expression and/or activity (Zender et al., 2006; Hunter et al., 2007; Imoto et al., 
2001; Keats et al., 2007; Inagaki, 2007; Altieri, 2003; Duffy et al., 2007; Bilim et al., 
2003; Yang et al., 2003).  While it is now clear that many IAP proteins can promote 
cancer development, the exact contributions of IAP proteins to cancer are unclear and 
might not be as simple as cell death inhibition, since it is now evident that many IAP 
proteins, including c-IAP1, function in additional signaling pathways that regulate such 
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 processes as the inflammatory response and cell proliferation.  Currently, there is much 
investigation to uncover the functional properties of IAP proteins that contribute to 
tumorigenesis. 
Table 4.1: Summary of cancers with alterations in IAP expression or activity. 
 
Several recent studies have identified c-IAP1 as a putative oncogene.  The BIRC2 
gene, which encodes c-IAP1, was present in an amplicon region associated with 
esophageal squamous cell carcinoma, where c-IAP1 expression correlated with resistance 
to chemotherapeutic agents (Imoto et al., 2001).  In a murine hepatocellular carcinoma 
genetic screen, the BIRC2 gene was also present in an amplified chromosomal region, 
and c-IAP1 was found to function synergistically with c-MYC (Zender et al., 2006).  
Subsequently, c-IAP1 was shown to target MAD1, the c-MYC regulatory factor, for 
proteasome-mediated degradation (Xu et al., 2007), supporting the idea that the E3 
ubiquitin ligase activity of c-IAP1 might be the important function for the oncogenic 
properties of c-IAP1.  Therefore, while it is now clear that c-IAP1 has oncogenic 
properties, it remains to be determined what functional roles of c-IAP1 are critical for it 
to function as an oncogene.  While the apoptotic inhibitory properties of c-IAP1 could be 
critical to inhibit cell death of cancer cells, the newly emerging roles described here for c-
IAP Cancer Reference
c-IAP1
Esophageal, hepatocellular, liver, lung & 
ovarian carcinoma; multiple myeloma
Zender et al. (2006), Hunter et al. (2007), 
Imoto et al. (2007), Keats et al. (2007)
c-IAP2 MALT lymphoma, multiple myeloma Inagaki et al. (2007), Keats et al. (2007)
Survivin
Lymphoma; Breast, colorectal, esophageal 
& gastric carcinoma Alteri D.C. (2003), Duffy et al. (2007)
XIAP
Bladder, breast, colorectal, & pancreatic 
carcinoma Yang et al. (2003), Bilim et al. (2003)
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 IAP1 in alternative signaling pathways such as NF-κB activation by TNF receptor 
might also be necessary for c-IAP1 to function as an oncogene, just as the E3 ubiquitin 
ligase activity of the RING domain is important for c-IAP1-mediated ubiquitination of 
MAD1 and might support synergy between c-IAP1 and c-MYC.   
Many important recent observations have come from the characterization of IAP 
antagonists developed by various research labs and pharmaceutical corporations 
(Varfolomeev et al., 2007; Vince et al., 2007; Petersen et al., 2007).  However, before c-
IAP proteins can become central targets for cancer therapeutics, it will be necessary to 
identify all cellular functions – both apoptotic and non-apoptotic, and it will be 
imperative to identify which of these functions are necessary and sufficient for the 
oncogenic function of c-IAP1.  Part of identifying the functional properties of c-IAP1 for 
tumorigenesis will also involve determining the mechanisms of regulating c-IAP1 
expression and activities.  This dissertation provides insight into the mechanisms that 
regulate and target c-IAP1, and in combination with future studies, will yield a thorough 
understanding of the signaling properties of c-IAP1 and the mechanisms critical for the 




In conclusion, this dissertation delineates the distinct mechanisms by which c-
IAP1 is regulated, and provides insight into the functional roles of c-IAP1 in apoptotic 
and non-apoptotic pathways.  These findings suggest that c-IAP1 is an important 
multifunctional signaling molecule, supporting recent studies suggesting that c-IAP1 is a 
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 putative oncogene that contributes to tumorigenesis.  Possibly the most surprising 
finding was the dynamic regulatory effects mediated by different c-IAP1 associating 
proteins, including TRAF2 and Smac/DIABLO, and the novel findings of the effects of 
these interactions on cell death and NF-κB signaling.  The findings in this dissertation 
provide evidence that the cellular effects of c-IAP1 on NF-κB activation and cell death 
inhibition are largely mediated by the interactions of c-IAP1 with its cellular binding 
partners that inhibit or promote the E3 ubiquitin ligase activity intrinsic to the RING of c-
IAP1.  Therefore, while it remains to be determined which properties of c-IAP1 are 
critical for its oncogenic function, it will also be important to determine whether the 
regulatory effects mediated by difference c-IAP1 associating proteins also contribute to 
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